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ABSTRACT 
This study assessed the effect that certain logistical and methodological factors in the 
laboratory could have on influencing precision and accuracy of enumeration of CD4+ cells. 
The efficacy of a new blood stabiliser to extend the window of CD4 testing, was also 
evaluated. 
CD4+ counts were derived using the 2-colour Pan-leucogating, 4-colour TetraONE and 
MultiTEST/TruCount protocols on the EPICS-XL, FC-500 or FACSCalibur flow 
cytometers. Statistical analyses included the paired-t-test, Spearman’s correlation and 
Bland Altman comparisons.  
The results showed that the reliability of CD4+ count results was heavily dependent on 
how blood samples were handled prior to and after receipt into the laboratory and on how 
samples were processed and analysed. The factors, motion, operator pipetting and analysis 
skills, storage temperature, use of different protocols, different gating strategies and the use 
of different flow cytometers, were found to influence accurate and precise enumeration of 
CD4+ counts. 
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1.0 INTRODUCTION 
1.1 Background  
Twenty eight years after the first reported death from Acquired Immune Deficiency 
Syndrome (AIDS), the epidemic continues to be the leading cause of death globally. It is 
estimated that 33 million people were living with the Human Immunodeficiency Virus 
(HIV-1) and 2 million deaths occurred worldwide from infection with HIV in 2007(1). 
Approximately 5700 deaths and 6800 new infections were estimated to have occurred daily 
in 2007(2). The deaths and incident cases seen over the years were mainly attributed to a 
lack of access to HIV prevention and treatment services(2).  
Concerted efforts to address these inadequacies at both national government level and 
globally, has resulted in a decline in the effects of the HIV epidemics worldwide. In 2007 
alone, a 16% decline was seen in the number of people living with HIV than were 
published in 2006(2). Seventy percent (70%) of this reduction in number was attributed to 
changes in estimates in six countries, five of which were in Sub-Saharan Africa(2) the 
region with the largest (67%) adult population globally infected and living with the 
virus(1).  
The drop in number of deaths and incident HIV infections has also been attributed to 
uptake of HIV prevention strategies and to increasing access to treatment and care 
programmes(1, 2). The number of people receiving antiretroviral treatment (ART) globally 
increased after the WHO/UNAIDS “3 by 5” initiative in 2003. In Africa, the increase was 
by 710,000 persons from 100,000 persons between the end of 2003 and 2005(3). Expanded 
access to ART inevitably increased the need for CD4+ counts to guide the initiation and 
monitoring of ART. With the G8 group of nations commitment to universal access to ART 
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by 2010, an even further need and availability of CD4+ monitoring services will be 
required(4). 
1.1.1 The Role and Importance of CD4+ Counts 
CD4+ T lymphocytes play a central role in the pathogenesis of HIV, and measuring them 
is one of the most important immunological parameters used in the staging and 
management of HIV infected patients(5-7). The number of CD4+ cells measured as 
cells/µl correlate with the clinical staging of HIV infection, progression to AIDS and 
mortality(8-11). CD4+ counts are of prognostic value as predictors of progression to 
AIDS(12), risk to development of certain opportunistic infections such as Pneumocystis 
carinii pneumonia, for guiding decisions on commencement and administration of 
ART(13, 14), prophylaxis of opportunistic infections(15-18) and as a surrogate marker for 
drug efficacy in clinical trials(19). CD4+ cell counts have also been shown to be essential 
in estimating the impact of HIV and ART administration on the epidemiological 
progression of tuberculosis and malaria in sub-Saharan Africa(20, 21). Accurate and 
reliable enumeration of CD4+ cell counts is therefore crucial if systematic evaluation of 
new therapeutic modalities and adequate monitoring of treatment to HIV infected persons 
is to be provided(3, 22). 
For effective management and monitoring of ART treatment, the World Health 
Organization (WHO) and United States Public Health Service recommended that HIV 
patient CD4+ cell counts be monitored every 3 - 6 months(23, 24). 
1.1.2 Overview of CD4+ Count Methods 
There are two main categories of CD4+ count methods, the manual non-flow cytometric 
methods and non-manual flow cytometric methods.  
Manual methods have a role in certain settings especially where small numbers (< 20) of 
samples are tested. Their use on a wider scale however, is impeded by a number of factors. 
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Manual methods are generally more error prone, less accurate and have poorer 
repeatability because their cell counts are based on smaller numbers counted, under a light 
microscope in a counting chamber (about 250 cells per analysis compared to 5000 – 10,000 
with flow cytometry) (25-31). Many of the manual methods have a poor ability to 
accurately enumerate CD4 T-cells because monocyte cells which also express the CD4 cell 
marker, and other sources of CD4 protein, tend to be counted along with the CD4 T- cells 
resulting in the generation of higher CD4+ cell counts than flow cytometry methods(26, 
27, 32). Many of the manual methods are also not able to provide percentage values critical 
in the management of paediatric patients, they generally lack effective external quality 
assurance assessment, are labour intensive(28, 33), time consuming, and subjective.  
The increase in treatment availability worldwide increased the need for faster, easier and 
more reliable methods for CD4 monitoring(34, 35). Flow methods, and in particular, the 
single platform technologies (SP), meet these criteria and would therefore be the most 
suited for the need ahead. SP methods have been shown to have better precision than the 
dual platform technologies (DP) both, within-(36) and between-laboratories(37, 38). They 
have also been shown to have better precision than the manual methods(31).  
1.2 Problem Statement 
Much technological advancement has been made over the years to improve the quality of 
CD4+ cell enumeration using flow cytometry(35). However, accurate enumeration of 
CD4+ counts remains a challenge due to the wide variation of CD4 methods used across 
laboratories, invariably leading to bias differences noted between laboratories.  
Many documented CD4+ flow techniques continue to be performed with poor precision 
(measured as the coefficient of variation [CV%]), with variability noted both within- and 
between-laboratories(30, 36-46). The main concern about variation of CD4+ counts is the 
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impact that the variation could have on influencing decisions related to treatment and 
management of HIV infected persons.  
Variation of CD4+ counts is typically reported to occur in both normal and HIV infected 
persons(47, 48) and has been attributed to two main reasons; biological factors(49) and 
methodological factors(42). It has been suggested that diurnal variation, a factor reported to 
account for nearly 50% of the measured variance of CD4+ counts(50), could be minimised 
by drawing blood samples at a specific time of the day(49, 51). Other cohort studies in 
patients with early or advanced HIV infection suggest that diurnal variability may be 
significantly blunted with disease progression and could therefore be negligible(49). While 
biological factors and specifically diurnal variation play some role, most documented 
variation of CD4+ counts has however been described in relation to technical differences 
e.g. differences in sample handling procedures(38) or differences in methods and 
instruments used(42). The major concern therefore, is the variance of CD4+ counts 
resulting from the technical differences within and between laboratories.  
Counts in the clinically relevant range (i.e around the 200cells/µl level) are more 
problematic. Variability of CD4+ counts and difficulties in attaining precision have been 
reported(6, 39, 40, 50), testing samples that have low CD4+ counts because these tended to 
show even higher levels of within-subject variation(6, 47). Studies that assessed within-
laboratory variation reported higher variability (median CV% >10%) for samples with 
lower CD4+ counts (≤ 200cells/µl)(36, 43, 44). Much greater variability (CV% as high as 
61.4%) mostly because of the variety of CD4+ count techniques used, has however been 
reported from external quality assessment (EQA) studies (trimmed data) and other studies, 
that looked at between-laboratory variation(36-38, 41, 43, 46, 52). 
A study that investigated whether use of a standard protocol (in this instance the use of 
CD45bright gating versus other variations of lymphocyte gating) would reduce inter-
laboratory variation, showed that about 77% of the variation in results of percentage 
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lymphocyte subsets could be attributed to laboratory, sample, background fluorescence, 
type of flow cytometer and flow cytometer setup(53).  
Difference (bias) in CD4+ counts between methods caused by inherent differences between 
instrument systems is not unusual and has also been reported in a number of studies(25, 33, 
40, 54-59) as shown in tables 1.1 and 1.2. Here, a range of differences described as 
“acceptable” between methods, some wide enough to alter decisions related to treatment 
and management of HIV patients, have been reported. 
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Table 1. 1: Bias (Mean Difference) between Flow Cytometry CD4+ Count Methods 
Study/Methods compared N Bias LOA 95% CI MPD(%) 
Median 
(ratio %) 10th %ile 90th %ile R2 
Strauss et al, 1996(45)                   
  DP flow vs FACSCount  118  N/R N/R N/R N/R N/R N/R N/R 0.986 
Lopez et al, 1999(60)                   
  In Salamanca: DP flow 
  vs FACSCount 24  N/R N/R N/R N/R N/R N/R N/R 0.979 
  In Barcelona:  DP flow  
  vs FACSCount 25  N/R N/R N/R N/R N/R N/R N/R 0.939 
Glencross et al, 2002(59)                    
U.K. NEQAS  evaluation                   
   Overall pool mean  
   vs DP PLG  20 -10 110 to -129 (18, -38) 0 ± 9% N/R N/R N/R 0.927 
   SP bead pool mean  
   vs DP PLG  20 -21 85 to -127 (4, -46) 2 ± 7% N/R N/R N/R 0.936 
   SP volumetric pool mean  
   vs DP PLG  20 -2.5 143 to -148 (31, -36) 1 ± 7% N/R N/R N/R 0.873 
   DP pool mean vs DP PLG  20 -14.5 109 to -138 (14, -43) 1 ± 9% N/R N/R N/R 0.918 
TransFix evaluation           N/R N/R N/R   
   SP volumetric vs SP beads  112 15.4 187 to -157 (31.6, -0.7) 4 ± 31% N/R N/R N/R 0.923 
   SP volumetric vs DP PLG  112 16.8 82 to -49 (23, -10.7) 6 ± 17% N/R N/R N/R 0.990 
   SP volumetric vs  
   DP Lymphocyte gated  112 46.2 368 to -275 (76.3, -16) 14 ± 51% N/R N/R N/R 0.758 
Pattanapanyasat et al, 
2005(54) 
                  
  SP volumetric CyFlow  
  vs SP TruCount  200 -69.1 87.5 to -225.7 N/R  N/R   N/R      N/R N/R 0.960 
  SP volumetric CyFlow  
  vs SP FACSCount  200 -40 85.1 to -165.1 N/R  N/R  N/R N/R  N/R 0.970 
Pattanapanyasat et al, 
2005(55)                   
  3-colour DP vs DP PLG 611 18 -97.4 to 133.1 N/R   N/R N/R  N/R  N/R  0.950 
Dieye et al, 2005(33)                   
  SP volumetric CyFlow  
  vs SP TruCount  121 -4 -121 to -114 (-14, -7) N/R  N/R  N/R N/R  0.970 
  SP volumetric CyFlow  
  vs FACSCount  121 -4 -161 to -153 (-18, -10) N/R  N/R  N/R  N/R  0.970 
  SP TruCOUNT  
  vs FACSCount   121 -12 109 to -134   (-23, -1) N/R  N/R  N/R  N/R  0.980 
Pattanapanyasat et al, 
2006(56)                   
  3-colour SP vs SP PLG 67 15.1 -26.2 to 56.4 N/R  N/R  N/R N/R  N/R  0.995 
Denny et al, 2008(40)                   
  Shipped samples  
     SP/DP vs DP PLG 495 45 N/R N/R  N/R 31 (0.89) -26 (0.68) 134 (1.11) N/R 
  Local samples  
     SP/DP vs DP PLG  58   N/R  N/R  N/R  23 (0.89) -23 (0.73) 112 (1.10) N/R 
Abbreviations: N/R – data not reported.  
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Table 1. 2: Bias between Different CD4+ Count Methods 
Study/Methods compared N Bias LOA 95% CI Median 10th %ile 90th %ile R2 
Landay et al, 1993(29)                 
  DP flow vs Cytosphere  382  N/R N/R N/R N/R N/R N/R 0.832 
Carella et al, 1995(25)                  
  DP flow vs Cytosphere  117 N/R N/R   N/R N/R   N/R N/R  0.930 
Denny et al, 1995(58)                  
  DP flow vs  
  Zymmune CD4/CD8  166  N/R N/R N/R N/R N/R N/R 0.940 
Lyamuya et al, 1996(27)                 
  DP flow vs FACSCount  173  N/R N/R N/R N/R N/R N/R 0.891 
  DP flow vs TRAx ELISA 189 N/R N/R N/R N/R N/R N/R 0.398 
  DP flow vs Dynabeads  189  N/R N/R N/R N/R N/R N/R 0.882 
Schnizlein-Bick et al, 2000(43)                 
  3-colour SP TruCount 
  vs 2-colour DP                 
     For Shipped samples 411  N/R N/R N/R 7 -67 79 N/R 
     On-site samples: 
          6 hours old 560  N/R N/R N/R 10 -29 72 N/R 
          24 hours old 560  N/R N/R N/R 2 -62 65 N/R 
Didier et al, 2001(30)                 
  3-colour SP TruCount  
  vs FACSCount 45 N/R N/R N/R N/R N/R N/R 0.971 
  3-colour SP TruCount  
  vs Cytosphere 55 N/R N/R N/R N/R N/R N/R 0.453 
  3-colour SP TruCount  
  vs Dynabeads 46 N/R N/R N/R N/R N/R N/R 0.913 
  3-colour SP TruCount 
  vs OptiCim 27 N/R N/R N/R N/R N/R N/R 0.717 
  3-colour SP TruCount  
  vs Capcellia 49 N/R N/R N/R N/R N/R N/R 0.423 
Diabouga et al, 2003(31)                 
  3-colour SP TruCount  
  vs Dynabeads 657 N/R N/R (-22, -8) -16 N/R N/R 0.890 
Spacek  et al, 2006(57)                 
  In Uganda: FACSCount  
  vs EasyCD4 141 -4.6 187.6 to -196.8 N/R  N/R  N/R  N/R  0.920 
  In United States : 
  DP vs EasyCD4 77 9 163.3 to -145.3 N/R  N/R N/R  N/R  0.970 
Karcher  et al, 2006(26)                 
  DP flow vs Cytosphere  131 -1.4 369 to -372 (34.1, 31.3) N/R N/R  N/R  0.526 
  DP flow vs  
  SP volumetric CyFlow 128 92 402 to -217 (65.1, 120.4) N/R  N/R  N/R  0.863 
Abbreviations: N/R – data not reported.  
 
The need to minimise variables that cause variation of CD4+ counts is therefore especially 
critical where HIV patient CD4+ counts are to be determined using different instruments, 
both within- and/or between-laboratories, across treatment networks or where CD4+ counts 
are used to determine endpoints across study-groups. This is particularly important because 
variation of the CD4+ counts could make longitudinal comparisons of the counts unreliable 
and could obscure their prognostic value. In this context, Sax P.E. et al, 1995(61), showed 
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that inter-laboratory variability in CD4+ cell counts could influence patient management or 
diagnosis of AIDS. In this study, laboratories reported different CD4+ cell counts for same 
patient samples and the variation in the counts was wide enough to cause conflicting 
diagnostic and therapeutic patient classification or qualification for either Mycobacterium 
avium complex (MAC) or Pneumocystis carinii pneumonia (PCP) prophylaxis.  
Variation between patient counts and variation of counts noted between laboratories needs 
urgent address. There is a need therefore to establish more standardised testing protocols 
and systems both within- and between-laboratories, to ensure generation of reliable CD4+ 
counts. Some guidelines are available for performing absolute CD4+ counts using flow 
cytometry(62-64). A first step towards addressing variability of CD4+ counts would be to 
ensure that these guidelines are uniformly applied by laboratories, at least within groups of 
laboratories servicing the same population of patients. 
 
This study assessed how certain logistical and methodological factors influence precision 
and accuracy of CD4+ cell enumeration in a laboratory. The study was carried in South 
Africa and Uganda using three widely used single platform (bead) protocols: (i) the 2-
colour PanLeucogate (2-colour FLOWCARETM PLG-CD4, BCI, Miami, FL)(59); and two 
4-colour systems, (ii) the TetraONE (BCI, Miami, FL)(36) and (iii) the 
MultiTEST/TruCount (MS/TC, BDB, San Jose, CA)(43). 
1.3 Hypothesis and Objectives 
The study hypothesizes that bias between two individual single platform flow techniques, 
used as described by the manufacturer and performed with absolute precision, will be zero 
or at least, consistent, if samples are handled and stored similarly. The objectives of this 
research were therefore:  
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i) To assess the impact of day-to-day sample handling and storage procedures such as 
temperature and motion, on the accuracy and precision of CD4+ cell counting. 
ii) To establish the possible ‘bias’ introduced with use of various methodologies and 
systems 
iii) To assess the impact some aspects of sample preparation specificially, pipetting 
methodology, have on the accuracy and precision of CD4+ cell counting 
iv) To assess the impact of delaying sample testing and to determine how long the testing 
period can be extended (time from collection to testing) to without undermining the 
quality (accuracy and precision) of the CD4+ results. 
  
 10
2.0 LITERATURE REVIEW  
2.1 CD4 Based Classification for HIV Infection and ART Initiation   
A CD4+ cell count of ≤ 200 cells/µl or CD4+ lymphocyte percentage of <14% is used by 
the U.S. Centers for Disease Control and Prevention (CDC) to define “AIDS” in HIV 
infected adults and adolescents(5). In HIV positive children, AIDS is defined as having an 
absolute CD4+ cell count of < 750 cells/µl for < 1 year olds; < 500 cells/µl for (1-5) year 
olds; < 200 cells/µl for (6-12) year olds; or a CD4+ T cell percentage of < 15% for all 
children irrespective of age(65). 
The World Health Organization (WHO) recommends ART for all persons in WHO clinical 
stage IV, regardless of CD4+ cell count; for all adults with CD4+ cell counts of < 200 
cells/µl, regardless of clinical stage, and for persons in stage III with CD4+ cell counts < 
350 cells/µl(3). For children, WHO treatment guidelines recommend that ART is initiated 
at a CD4+ cell count of < 200 cells/µl, regardless of clinical stage(3), at a CD4+ cell count 
of < 1500 cells/µl for ≤ 11 months old; at < 750 cells/µl for 12 – 35 months old; and at < 
350 cells/µl for 36 – 59 months old(66).  
2.2 Trends in Use of CD4+ Tests  
The number of CD4+ cell count tests performed annually in South Africa increased with 
the introduction of ART programmes and continues to grow with increased access to 
treatment(67). Subsequent to the implementation of the National ART Programme in South 
Africa, a more than double increase was noted with testing, increasing from 303,351 tests 
in 2004/5 to 704,131 tests in 2005/6(68). An even greater need for CD4 laboratory services 
was seen in 2007(39, 69) during which the number of CD4+ cell count tests performed in 
2006/7 (1,566,276 tests), was more than twice that in previous years; (704,131) in 2005/6. 
These figures were based on the reported number of tests done by approximately 35 newly 
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appointed National Health Laboratory Service (NHLS) CD4 laboratories performing 
PanLeucogated CD4 lymphocyte testing. In 2007/8, these figures increased to 1.96 million 
CD4 tests performed across more than 56 SA-NHLS laboratories(70). Annual figures of 
CD4+ cell count tests done by the CDC laboratory in Uganda were 30,287, 22,235, 21,711 
and 19,159 in 2005, 2006, 2007 and 2008 respectively (personal communication – 
Kusemererwa A., CDC-Entebbe, Uganda). These data clearly indicate that the demand and 
utilisation of CD4+ cell counts in sub-Saharan Africa is high and is on the increase.  
2.3 CD4+ Enumeration Techniques 
CD4+ count techniques can be divided into two main categories, the manual (non-flow 
cytometric) methods and flow cytometric methods.  
Manual (Non-Flow Cytometric) technologies include:  
i) Microscopy bead assays such as the Cytospheres assay (Coulter Corporation, Florida, 
USA) in which antibody coated with latex spheres binds CD4-expressing cells to form 
CD4 cell-sphere rosettes that are then identified and counted in a counting chamber 
using a light microscope(25, 26, 29). The magnetic bead Dynabead method (Dynal, 
Compiégne, France)(27, 28) and the  Immunoalkaline Phosphatase assay(71-73), both 
of which also require a counting chamber for cell counting.  
ii) Enzyme Linked Immunosorbent assays (ELISA) such as the Total Receptor Assay 
(TRAx CD4) (T Cell Diagnostics, Inc. [TCD], Cambridge, Mass.)(74, 75), Zymmune 
fluorescence assay (Zynaxis, Inc., Malvern, Pa.)(58, 76) and Whole Blood Capcellia 
CD4/CD8 (Sanofi diagnostics Pasteur, Marnes la Coquette, France)(77), (all no longer 
commercially distributed). 
iii) The dried whole blood spot assay (Filter paper ELISA)(proposed as a potential 
alternative method for CD4 count measurement)(78).  
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 Flow cytometric methods include:  
i) Dual platform (DP) methods: These methods use two different instruments, a flow 
cytometer and a haematology analyser to obtain two separate values used in the 
derivation of absolute CD4+ cell counts. The flow cytometer is used to obtain a CD4+ 
lymphocyte percentage of total lymphocytes in the conventional method(79), or in the 
case of the DP PanLeucogated CD4 counting (DP PLG), to obtain a CD4+ lymphocyte 
percentage of total blood leukocytes(59). In the conventional DP CD4 method, a 
haematology analyser (HA) is used to obtain a Total Lymphocyte Count (TLC) 
(derived from a total white cell count (WBC) and lymphocyte differential) which is 
then used as the reference population for calculating absolute CD4+ counts and the 
CD4% amongst total lymphocytes(63, 79). In DP PLG the WBC and not the TLC, is 
used as the reference population for calculating absolute CD4+ counts(59). Because DP 
PLG avoids use of TLC the main variable in conventional DP testing, it has been 
shown to improve within- and between-laboratory precision to a level similar to that of 
SP methods(40, 59).   
ii) Single platform (SP) flow cytometry methods: These methods use one instrument (a 
flow cytometer) to directly provide absolute cell counts. They are of two kinds:  
 Flow cytometers that support bead-based methods: These methods use a known 
volume and concentration of beads that are added to the sample during sample 
preparation and act as the reference population from which the cell 
concentration per unit of blood is calculated. These include: The FACSCount 
(BDB, San Jose, CA) a modified, portable flow cytometer that uses a green 
laser, two-colour monoclonal antibody reagent, calibrated reference beads and 
control beads(45); the SP PanLeucogate (PLG-CD4)(39, 59) and TetraONE T-
Cell (Beckman Coulter, Miami, FL)(36, 46) methods that use beads suspended 
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in liquid; and the MultiTest/Trucount (BDB, San Jose, CA)(43, 80, 81) method 
which uses lyophilised beads. However, any bead enumeration products can be 
used with any antibody combination to derive SP CD4+ counts. 
 Volumetric methods: These do not require reference beads to calculate absolute 
cell counts but may use beads as internal quality control tools to ensure 
reliable volumetric CD4 measurements. Volumetric methods are available 
as: 
i) Methods that use a built-in syringe system to deliver a unit volume of blood 
for analysis such as; the 2-colour Guava Easy CD4(57, 82, 83) and Guava 
PCA(84) microcapillary flow cytometry systems that require small sample 
volumes (10µl) and do not use sheath fluid; PointCare and  PointCare Now 
(PointCare Technologies)(85, 86), which are fully automated systems that 
operate with collidal gold-labeled reagents, and combine flow cytometry 
and hematology analysis. These compact, portable, instruments detect 
scattered light at four different angles all at once and use the light and not 
fluorescence signals, to identify and emunerate cells; Cytoron-Absolute 
(Ortho Diagnostics) although it is obsolete (87, 88); hybrid multitasking 
flow cytometers such as the Luminex 100 (Luminex Corporation, Austin, 
Tx.)(89, 90) and the FACSArray (BDB, San Jose, CA). 
ii) Methods that use an electrode volumetric option such as; the Cyflow SL 
blue multi-parameter cytometer equipped with a 488 nm blue laser (33) and 
the single or dual-parameter CyFLOWgreen cytometer equipped with a 532 
nm green laser, from Partec GmbH, Münster, Germany(54, 91). Cell counts 
on these cytometers are based on using a fixed volume of sample. This 
process is achieved by using two electrodes that automatically detect the 
sample fluid level and initiate and stop the sample acquisition process. 
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iii) Methods that use the dual syringe and electrode volumetric options e.g. the 
single-parameter Partec CyFlow Counter that is equipped with a 532 nm 
green laser (Partec GmbH, Münster, Germany)(28, 92, 93). 
2.4 Comparison of Flow Methods 
Several studies(40, 45, 55, 59, 60) have looked at the performance and reliability of CD4 
testing using the two types of flow methods (DP and SP) mentioned in section 2.3. Studies 
that specifically compared conventional DP and SP flow methods showed the conventional 
DP methods to have much higher variability(36, 37, 94). The high variability and bias seen 
with these conventional DP methods has been attributed to the use of different machines 
(flow cytometers and haematology analysers) and to the use of the total lymphocyte count 
(TLC) to derive absolute CD4+ counts(95, 96). Haematology analysers have several other 
disadvantages. In particular, they have a narrow window of testing (6 hours) within which 
reliable white blood cell differentials can be generated(95). The instruments also generally 
lack internal quality control and external quality assessment for the WCC differentials(87, 
95), and are calibrated using blood cell controls that have wide ranges(50). These factors 
coupled with the fact that the instruments differ in operation i.e. how they differentiate and 
measure lymphocytes(96) with some using just the cell volume (size) as opposed to a 
combination of both volume and light scatter features (the Volume Conductivity and 
Scatter/Absorbance Cytochemistry and Volume principle), may compromise the precision 
of derived absolute lymphocyte counts.  
Because SP technologies provided more reliable results and overcome the limitations of 
the conventional DP systems, they have become the and gold standard for CD4+ cell 
enumeration in several laboratories(45, 46, 87, 94, 97). 
Given the rate ART implementation programmes are envisaged to expand, the availability 
and timely delivery of CD4 monitoring services to support the expansion of these 
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programmes, will be necessary. For this to be accomplished, quality CD4+ count 
methodologies with a capacity for high workloads and fast turn-around time will be 
required. SP flow cytometry methods have demonstrated these capabilities and appear to 
be the most suitable platform for effective implementation of ART programmes(39). 
2.5 Factors that cause Variation in CD4+Cell Counts 
Variability of CD4+ cell counts can be caused by biological factors and methodological 
factors. 
The biological factors include:  
i) Age: Absolute WBC counts tend to decrease with age. Higher CD4+ counts are seen in 
children than in adults(98-100), in younger persons than in the elderly (>50 
years)(101), and in neonates and infants (≤12 months), who have higher counts than 
older children(99, 102). 
ii) Gender and Hormonal effects:  Females have been shown to have higher CD4+ cell 
counts than males(48, 98, 103, 104). Among ovulating females, pre-ovulation and 
menstruation have been associated with higher CD4+ percents than post-
ovulation(103). Estrogen has been suggested as a possible explanation for the 
difference in CD4+ counts seen between the genders(103, 105).  
iii) Diurnal and Circannual variations: Diurnal and circannual variation of CD4+ cell 
counts in HIV positive and HIV negative populations has been documented in several 
studies(47, 49, 51, 106, 107). The lowest CD4+ counts (nadir) and highest counts in 
healthy HIV-negative adults with normal sleep/wake cycles, are reported to be seen in 
the morning hours (0800-1100 hours) and evenings (2000-2200 hrs), respectively(49, 
51, 108). Studies have also shown lymphocyte cell counts to vary with the seasons of 
the year (winter, spring, summer and autumn)(48, 108, 109). Possible explanations for 
the contrast in counts have included, trafficking and compartmentalisation of the 
  
 16
lymphocytic cells in and out of blood and other body organs (bone marrow, lymph 
nodes, spleen)(106), or as a result of diurnal and circannual patterns of cortisol, 
exposure to light, or emotions(51). 
iv) Recent/Concomitant Infections: Viral infections such as cytomegalovirus infection, 
bacterial infections such as tuberculosis(105), sexually transmitted diseases(110), 
parasitic (helminthic) infections, and other disease conditions like malnutrition, 
marasmus(111), Hepatitis B, P. carinii pneumonia, iron deficiency(112), autoimmune 
thyroiditis(113), bronchial asthma(114), have been associated with causing alterations 
in lymphocyte cell homeostasis. 
v) Splenectomy: Is shown to cause elevation of CD4+ cell counts probably as a result of 
lymphocytosis(115, 116).  
vi) Physical Stress: Has been suggested to cause an increase in lymphocyte subsets(117). 
vii)  Exercise and Rest: While acute strenuous exercise has been associated with 
lymphocytosis followed by relative lymphopenia in the immediate recovery period, 
brief periods of rest (30 and 60-minutes) from normal activity have been associated 
with decline in CD4+ cell counts(118). 
viii) Ethnic Origin and Geographical Location: Variation in CD4+ counts is said to 
occur between regions and within and among populations(98, 119-122). Altitude, 
exposure to different pathogens and infections, genetic differences, environmental and 
nutritional factors, have been offered as plausible explanations for the variation in 
lymphocyte subsets within and among populations. 
ix)
 Smoking: Was found to be associated with an increase in absolute CD4+ cell counts, 
leucocytosis, lymphocytosis and increase in CD4 percentages(103, 123). 
x) Drugs: ART enhances T-cell reconstitution through restoration of thympoiesis(124, 
125), however, other medicines e.g. cephalosporins, corticosteroids and 
glucocorticoids(126, 127) have been associated with a trend towards lower absolute 
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CD4+ cell counts. Alcohol use has also been associated with lowering of CD4+ cell 
counts(128).  
 
Methodological influence on CD4+ counts is shown to arise from procedures related to 
how whole blood samples are handled and processed after draw, and from methods 
employed in analysis and reporting of results. Factors that influence the accuracy and 
precision of CD4+ lymphocytes counts include: 
i) Anticoagulant. The type of anticoagulant used(129) and incorrect blood to 
anticoagulant ratio which can arise from incorrect filling of blood collection tubes or 
use of liquid anticoagulant (acid citrate dextrose or heparin), can affect accurate 
enumeration of absolute WBC and lymphocyte subset counts(64, 130). Improper 
mixing of blood with the anticoagulant could also lead to clotting and erroneous results 
if clotted specimens are analysed. Better reproducibility of cell counts was observed 
when adequate draws of blood were made i.e. 3-4ml of blood in 5ml EDTA vacutainer 
tubes than was when inadequate volumes were drawn i.e. draws of 1-2ml or 5ml of 
blood in 5ml collection tubes(130).  
ii) Temperature: Varying degrees of sample deterioration can occur depending on how 
and at what temperature samples are stored and handled from the time of draw to when 
they are processed in the laboratory. It is generally recommended that whole blood 
samples are stored at room temperature (18 – 22ºC) as increases in temperature can 
result in large variation of CD4+ counts from baseline at room temperature(63, 64). 
Storage at 4ºC has also been suggested since no significant loss of lymphocyte cells 
occurred from storage of samples at refrigerator temperature(131). However, extreme 
temperatures hot or cold, could affect the accuracy of flow cytometry measurements.  
Temperatures ≥ 37ºC have been shown to cause cell death(131). 
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iii) Interval from draw of blood to analysis (Sample Age): Major changes in the light 
scatter patterns of leucocytes and the respective cell differential counts have been 
shown to occur when whole blood is kept for periods longer than 12-24 hours before 
analysis. These changes, combined with the inherent variability of different 
instruments, could result in considerable variation in reported absolute CD4+ 
counts(95, 96, 130). 
iv) Antibody Staining: Different staining protocols have been shown to give different 
results(132, 133). When using commercial reagents, deviation from the manufacturer 
protocol in terms of the volume of antibody used, the time and temperature of 
incubation with antibody reagent and the blood volume, could cause changes of 
staining intensity. Fluorochrome associated variation was observed with higher 
measurements with phycoerythrin (PE) than with fluorescein isothiocyanate (FITC)(97, 
134, 135). Change of reagent lots could also result in differences in T-cell subset 
counts.  
v)
 Nature of Lysing Reagents: The acidic nature of erythrocyte (RBCs) lysing reagents 
reduces sample pH which could affect the integrity of cell membranes or alter flow 
cytometric light scatter patterns and surface staining characteristics of WBCs. Changes 
in sample pH may also cause dissociation of some antibody/antigen complexes and 
cause variation in cell counts(136-139).  
vi) Sample Preparation Methods (Cell Lyse and Fixation Procedures): There are three 
techniques commonly used to prepare WBCs for flow cytometric analyses; the Lyse-
and-Wash (LW) technique(140, 141); Lyse-No-Wash (LNW)(140) and the No-Lyse-
No-Wash technique(NLNW)(33). The LW technique involves a RBC lyse step and 
subsequent wash and centrifugation steps to remove the lysed RBCs before a final 
WBC fix step. In the more commonly used LNW technique which excludes any cell 
wash steps, lysis of RBCs and fixation of the WBCs occur in a single step. With the 
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NLNW technique, whole blood is neither lysed nor washed. It has been reported that 
fixatives can change the light scattering profile and fluorescence intensity of cells(142) 
and that wash procedures could cause significant cell loss(139, 140). Vortexing and 
centrifugation procedures have also been reported to damage malignant and/or 
activated cells that are fragile or differ in buoyant density from normal cells(133, 143). 
Additionally, cell loss may occur because of adherence to containers or failure to form 
complete pellets after wash and centrifugation procedures. Lower variation and tighter 
CVs for absolute CD4+ cell counts were observed when LNW or NLNW techniques 
were used suggesting that greater cell loss occurred during wash procedures in the LW 
technique(46, 140). Variability of lymphocyte cell counts may also result from 
inadequate mixing of blood and the reagents (antibody, lyse/fix solution) or from the 
interference of light scatter patterns of unlysed nucleated erythroid cells with 
lymphocyte scatter patterns(38, 53). 
vii) Pipetting of Blood and/or Beads: There are two types of beads commonly used in 
single platform (SP) flow methods; the liquid form such as FlowCount beads, or the 
preloaded lyophilised form such as TruCount beads. Accuracy of bead-based counts is 
dependent on the precision of the pipetting steps i.e. of the blood and/or beads. 
However, several other factors could also affect the pipetting steps and thus the 
accuracy of absolute bead-based counts. These factors include, inadequate resuspension 
of bead solutions after storage which can cause changes in the proportion of beads 
aspirated and the use of inappropriately calibrated/faulty pipettes(144). The latter is 
especially relevant for protocols that use preloaded lyophilised beads as these protocols 
have a single pipetting step i.e., that of blood. The single pipetting step increases the 
probability of introducing errors due to pipette variability, errors that would otherwise 
be minimised if the same pipette is used to pipette both blood and beads. Use of wrong 
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pipette tips, the pipetting technique employed e.g. reverse pipetting described in 
Appendix B, is the recommended technique(64, 144) for methods that use lyophilised 
bead products, and poor pipetting skill which results in incorrect dispensing of either 
blood or beads or both, could also affect the pipetting steps. Errors may also arise as a 
result of reduction of bead concentration in suspension (vanishing bead phenomenon) 
caused when protein-free or protein-poor samples are vortexed(145), or due to use of 
incorrect bead counting gating strategies i.e., CD4 techniques that use TruCount beads 
require the bead counting strategy to include all singlet and doublelet bead aggregates 
while techniques that use FlowCount beads require inclusive of only the singlet 
beads(144).   
viii) Instrument Characteristics: Lack of uniformity in the method and instrument used 
for CD4 testing(134, 135), differences in instrument set-up (compensation settings, 
type and level of threshold [also called “discriminator”] settings)(46), differences in 
instrument sensitivity to different fluorochromes(134) as well as protocol setups 
including choice of ‘live” gates and order in which they are used, could influence 
accurate enumeration of CD4+ T cells.  
ix) Data Analysis: Choice of gating strategy and the quality of the lymphocyte gate (i.e. 
exclusion of non lymphocyte cells from the lymphocyte gate) can have a significant 
effect on results obtained(46, 97). Nonlymphoid cells such as monocytes, unlysed 
nucleated erythroid cells, basophils, immature cells and artifacts such as cell aggregates 
and platelet clusters could interfere with lymphocyte purity and not be easily identified 
or excluded if light scatter (forward scatter [FSC] and side scatter [SSC]) gating is used 
alone(144). Methods that employed CD45 and SSC-based gating of lymphocytes have 
been shown to have lower variation and greater lymphocyte purity than methods that 
used light scatter-based gating or CD45 and CD14 backgating strategies(46, 146).  
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2.6 Measures to Reduce Variation of CD4+ Counts 
In addition to promoting the use of robust SP technologies, a number of other measures 
have been suggested to improve the quality of CD4+ counts. These include amongst others, 
provision of adequate training to laboratory personnel(53) and use of stringent internal 
quality controls or other quality control tools such as the bead count rate (BCR) to monitor 
the sample preparation process, specifically quality controlling the pipetting of beads 
and/or blood(39, 147). Participation in external quality control assessment schemes (EQA) 
has also been shown to have an impact on the performance of laboratories(37, 41, 52). A 
study by the Canadian International Programme for Quality Assessment and 
Standardisation for Immunological Measures relevant to HIV/AIDS (QASI) showed a 
decrease in inter-laboratory variability of CD4+ counts from 14.2% to 8.8%, with 
increasing participation(52). In the African context, use of simplified technologies such as 
FACSCount and PLG (both as DP or SP), has been shown to significantly improve on 
reproducibility and precision between laboratories(39). Other measures have included 
standardising of CD4+ protocols since this demonstrated more reliable inter-laboratory 
performance(39, 45, 46, 60, 87, 97, 148), use of universal templates(149, 150) and 
adherence of laboratories to good clinical laboratory practice(151). 
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3.0 METHODOLOGY 
This study was carried out at the SANAS accredited NHLS Flow Cytometry Laboratory at 
the Johannesburg Hospital in South Africa and at the CDC laboratory in Entebbe-Uganda. 
The reason the study was done in two countries was to provide a means of evaluating the 
impact that different conditions could have on local CD4 testing reproducibility, including 
different population groups, different geographical and climatic settings and different 
laboratory logistics. 
Both laboratories participated in external quality control assessment programmes for 
leucocyte immunophenotyping. The Johannesburg laboratory participated in UK-NEQAS, 
the African Regional External Quality Assessment Scheme for CD4+ Lymphocyte 
Enumeration (AFREQAS)(41), Quality Assessment and Standardisation for 
Immunological Measures Relevant to HIV/AIDS scheme (QASI), as well as in the 
Beckman Coulter Inter-laboratory Quality Assessment Programme (IQAP). The CDC 
laboratory participated in the UK-NEQAS, College of American Pathologists (CAP) and 
QASI schemes. It needs to be noted however that the performance of the operator (the 
writer) could not be accomodated in any of these external quality control assessment 
schemes and was not assessed on these programmes. Within-operator precision of the 
operator was however assessed. 
3.1 Ethics Clearance 
This study was approved by the ethical committee of the University of the Witwatersrand, 
Faculty of Health Sciences Committee for Research on Human Subjects (Reference 
Protocol Number: M070231) and the Science and Ethics Committee of the Uganda Virus 
Research Institute (Reference Number: GC/127/04/07). 
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3.2 Blood Samples  
A total of 286 K3EDTA (BDB) adult (> 18 years) blood samples were used in this study. 
One hundred and ninety seven (197) of the 286 samples were selected from samples 
received for routine CD4+ testing at the laboratories on the basis that they were < 24 hours 
old. The remaining 89 of the 286 were samples specifically drawn in (1ml) blood 
stabilisation vacutainer tubes (BDB) to evaluate the ability of this new commercial product 
to extend the window of CD4 testing.  
One hundred and thirty-eight of the 197 samples were received and analysed at the 
Johannesburg laboratory and 59 were samples received at the CDC laboratory in Uganda.   
Twenty (20) of the 89 samples drawn in 2 ml blood stabilisation vacutainer tubes were 
collected in Johannesburg and were first processed within 4 hours from the time of draw 
(the samples were tested over several consecutive days). The remaining 69 blood 
stabilisation samples were collected in Uganda and were processed within 48 hours from 
the time of draw. These 69 samples were however > 24 hours old at the time of receipt at 
the CDC laboratory. 
3.3 Enumeration of CD4+ Cells 
CD4+ cell count enumeration was performed using three known, standard, single platform, 
bead based, Lyse No-Wash methods: 4-colour MultiTEST/TruCountTM (MS/TC, 
BDB)(43); TetraONETM with FlowCount (BCI, Miami, FL)(36); and the 2-colour 
PanLeucogateTM CD4 with FlowCount (2-colour PLG-CD4, BCI, Miami, FL)(39). The 
methods were performed in accordance to stipulated manufacturer instructions. All three 
methods were used for this study at the Johannesburg laboratory: 2-colour PanLeucogate 
was the predicate CD4+ cell count protocol at this laboratory.  
4-colour MultiTEST/TruCount was the predicate CD4+ cell count method at the CDC 
laboratory and used for all studies performed at this laboratory. 
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3.3.1 Preparation of Samples 
i) Procedure followed for the 4-colour TetraONE CD4 Method. 
Test tubes (BCI, Miami, FL) were setup (labeled) to correspond to the laboratory number 
of samples. TetraCHROMETM monoclonal antibody reagent 
(CD45FITC/CD4RD1/CD8ECD/CD3PC5) (BCI, Miami, FL) (5µl) was added to each 
tube,  followed by the addition of (100µl) of well mixed whole blood.  The tubes were 
gently vortexed (5 seconds), placed within a carousel and loaded on a Multi-Q-PrepTM 
work station (BCI, Miami, FL) to incubate for 10 minutes before the automated lyse 
procedure described in section 3.3.1 (iii) was commenced. After the latter sample 
preparation step and immediately prior to analysis, FlowCOUNTTM beads (BCI, Miami, 
FL) (100µl) were added to each sample using the same pipette used to dispense the blood. 
The tubes were each vortexed once, re-placed back into the carousel and loaded onto the 
flow cytometer for acquisition. Listmode data was saved for retrospective re-analysis of 
outliers, if required. 
Listmode data was also used to evaluate the bias potentially introduced between different 
gating strategies. In other words, the TetraONE 4-colour listmode data was re-analysed 
using a 2-colour PLG strategy. Such re-analysis of data allowed for true assessment of 
impact of gating on bias between CD4+ counts. Here, all aspects of biological sample 
variation as well as variation introduced through sample preparation and technical 
instrument variation during flow cytometric analysis are effectively removed. 
 
ii) Procedure followed for the PLG-CD4 Method 
Test tubes (BCI, Miami, FL) were setup (labeled) to correspond to the laboratory number 
of samples. FlowCARE antibody reagent (CD45 FITC/CD4 PE) (BCI, Miami, FL) (10µl) 
was added to each tube, followed by the addition of (100µl) of well mixed whole blood. 
The tubes were gently vortexed (5 seconds), placed within a carousel and loaded on a 
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Multi-Q-PrepTM work station (BCI, Miami, FL) to incubate for 10 minutes before the 
automated lyse procedure described in section 3.3.1 (iii) was commenced. After the latter 
sample preparation step and immediately prior to analysis, FlowCOUNTTM beads (BCI, 
Miami, FL) (100µl) were added to each sample using the same pipette used to dispense the 
blood. The tubes were each vortexed once, re-placed back into the carousel and loaded 
onto the flow cytometer for acquisition. Listmode data was saved for retrospective re-
analysis of outliers, if required. 
PLG prepared samples were also used to evaluate the bias potentially introduced between 
different models of flow cytometers from the same manufacturer. In other words, the PLG 
prepared samples were run on the Epics-XL and re-analysed on the FC-500. Such re-
analysis of data, where all aspects of biological sample variation as well as variation 
introduced through sample preparation were effectively removed, allowed for true 
assessment of impact of instrument variation during flow cytometric analysis on bias 
between CD4+ counts. 
 
iii) Description of the Sample Lysis Procedure using the Multi Q-PrepTM Work 
Station 
Sample lysis using the Multi Q-PrepTM work station (BCI, Miami, FL) is a 35 second 
automated process in which Beckman Coulter Immunoprep reagents (A), (B) and (C), are 
each added to a sample.   
Lysing solution (Reagent A: Formic Acid and Stabiliser) (600µl) is added to the sample to 
lyse erythrocytes and the tube is mixed and allowed to stand for 8 seconds. Stabilising 
solution (Reagent B: Sodium Carbonate/ SodiumChloride/ Sodium Sulphate/ Stabiliser) 
(265µl) is then added and the sample mixed and allowed to incubate for 10 seconds. 
Fixative (Reagent C: Paraformaldehyde and Buffers) (100µl) is finally added to the sample 
and the tube mixed and allowed to stand for 10 seconds. The prepared sample is rendered 
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non-infectious with the addition of paraformaldehyde and the sample is stable for analysis 
for up to one week post sample preparation, if stored at refrigerator temperature (4°C). 
 
iv) Procedure used for the MultiTEST/TruCount CD4 Method 
TruCount tubes (containing preloaded lyophilised beads) were setup (labeled) to 
correspond to the laboratory number of blood samples. MultiTESTTM antibody reagent 
(CD3-FITC/CD8PE/CD45PerCP/CD4APC) (20µl) was added to each tube, followed by 
the addition of (50µl) of well mixed whole blood of the appropriate sample. The tubes 
were gently vortexed (5 seconds) to ensure thorough mixing then placed in the dark to 
incubate for 15 minutes at room temperature. FACSTM lysing solution (BDB) (450µl) 
diluted in a 1:10 ratio with distilled water was added to each sample to stop the reaction 
and fix the cells. The tubes were gently vortexed and allowed to incubate for another 15 
minutes at room temperature. A work-list of the prepared samples was created and the 
samples arranged onto a carousel in the order of the list and loaded onto the FACSCalibur 
for acquisition and analysis. The prepared sample is rendered non-infectious with the 
addition of formaldehyde and the sample is stable for analysis for up to 24 hours post 
sample preparation, if stored at room temperature (20-25°C).  
Created listmode data files were saved for retrospective re-analysis of samples flagged for 
having questionable integrity. The data files were also used to evaluate the bias potentially 
introduced between different manufacturer systems as well as bias potentially introduced 
between different gating strategies. In the latter case, the 4-colour MultiTEST/TruCount 
data was re-analysed using a 2-colour PLG strategy to allow true assessment of impact of 
gating on bias between CD4+ counts using the Becton Dickinson system. 
  
 27
3.3.2 Flow Cytometry 
3.3.2.1 Instrumentation used for the Laboratory Procedures 
Samples were analysed using flow cytometers that allow for four–colour data acquisition. 
The cytometers used were: 
i) The EPICS XL flow cytometer (BCI, Miami, FL) equipped with a blue 488 nm argon 
laser 
ii) The Cytomics FC-500 flow cytometer (BCI, Miami, FL) equipped with a blue 488 nm 
argon laser and a 635 nm red diode laser (the latter mentioned was not used for the 
purposes of this study) and 
iii) The FACSCalibur (BDB) equipped with a 488 nm argon-ion laser and a 635 nm red 
diode laser. 
The Johannesburg laboratory had all three cytometers and the CDC laboratory had just 
one, the FACSCalibur (BDB). 
 
For each assessment of variability carried out, blood (and for the Beckman Coulter 
methods, the fluorescence beads) was measured using a specific pipette.  The three pipettes 
used (referred to as pipette A, B and C respectively from here on) were; 
i) (100µl) fixed volume pipette (Gilson Inc., WI, USA), (pipette A) used in Johannesburg 
ii) (200µl) pipette (Gilson Inc. WI, USA), (pipette B) used at the CDC laboratory 
iii) (20-200µl) Eppendorf pipette (Brinkmann Instruments, Westbury, N.Y), (pipette C) 
also used at  the Johannesburg laboratory. 
Pipetting was performed using Diamond D200 (200ul) pipette tips (Gilson Inc. WI.USA). 
Other instruments used in general standard procedures such as calibration of pipettes and 
vortexing, are listed in Appendix A. 
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3.3.2.2 Acquisition and Analysis of Samples using the TetraONE Protocol 
 The TetraONE protocol, used at the Johannesburg laboratory, uses 4-colour analysis and 
the CD45bright lymphocyte gating strategy to derive absolute CD4+ cell counts. It is 
however possible to apply both the 4-colour CD45bright lymphocyte gating strategy and the 
2-colour PLG gating strategy in a single acquisition and analysis to facilitate the 
simultaneous generation of both a CD45bright/CD3 gated CD4+ lymphocyte count as well 
as a PLG CD4+ lymphocyte count. Such a strategy effectively uses the same set of 
listmode from a single sample acquisition to assess the contribution of gating to bias 
between CD4 methods. 
In this 4-colour analysis (aspects identified within a red box in Figure 3.1), total 
lymphocytes were identified as bright CD45++/low SSC events and defined in the CD45 
fluorescence/SSC scatter plot [gate B in scatter plot 2 of Figure 3.1]. CD3+4+ and CD3+8+ 
T-cells within this CD45++ lymphocyte gate were identified [region F and region G 
(populations shown by red dotted lines) in Scatter plot 6 and 7 respectively, of Figure 3.1] 
and using the FlowCount bead population (identified as a single, very bright, tight 
population in the light scatter scatter plot [FSC versus SSC]: Scatter plot 1 in Figure 3.1), 
the CD4 and CD8 absolute cell counts of the total CD3+ lymphocytes derived using the 
formula: 
(Number of CD3+CD4+events) / (Total number of beads acquired) x (Number of 
beads/µl). Note: CD3+CD8+events were used in the calculation of the absolute CD8 count. 
The CD4% lymphocyte count was derived using the formula: 
[Total CD4+ lymphocyte events (events in gate D) / [Total lymphocyte events (events 
in gate B) x 100. 
The CD8ECD vs. CD4PE scatter plot identified within a green box in Figure 3.1, was used 
to monitor color compensation. 
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An explanation of how absolute CD4+ counts were derived when the 4-colour TetraONE 
listmode data was re-analysed using the 2-colour PLG strategy [using only the data related 
to the CD45 and CD4 acquisition parameters of the 4-colour listmode data set – data in 
scatter plot 2 and 3 enclosed in a solid blue rectangle in Figure 3.1], is provided in section 
3.3.2.3 that describes 2-colour PLG acquisition and analysis.  
In the 2-colour PLG analysis, bright CD4++ within the lymphocyte gate [region D in scatter 
plot 4, identified within a blue dotted blue box in Figure 3.1], were used to derive the 
CD4% count, in a similar fashion to the CD4% of lymphocytes generated within the 
CD45bright gated protocol. 
An illustration of the TetraONE protocol performed incorporating both the 4-colour and 2-
colour gating strategies in a single acquisition and analysis on the same sample, is shown 
in Figure 3.1. 
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Figure 3. 1: Figure to illustrate the derivation of CD4+ counts and CD4% of Lymphocytes using the 
CD45bright Lymphocyte Gating Strategy and the 2-colour PLG Gating Strategy in a Single Acquisition 
and Analysis using the Johannesburg TetraONE protocol on a Beckman Coulter Instrument. 
3.3.2.3 Acquisition and Analysis of Samples using the 2-colour PLG-CD4 Protocol 
The PLG-CD4 is a 2-colour based method that uses total leucocytes (CD45+events) as a 
reference population for calculating absolute CD4+ cell counts.  
It is the predicate CD4+ cell count method used at the Johannesburg laboratory. Routine 
clinical samples, prepared following this 2-colour PLG-CD4, were analysed on the Epics-
XL (BCI, Miami, FL) and on the FC-500 (BCI, Miami, FL) flow cytometers. This re-
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acquisition of samples was performed to assess how using a different platform (instrument) 
of sample data acquisition impacts and contributes to bias between CD4 methods. 
In the PLG analysis (scatter plots enclosed in a blue rectangle), a “Panleucogate” 
identifying all CD45+ events (total leucocytes) was first defined in the CD45 
fluorescence/SSC scatter plot [gate A in Scatter plot 2 of Figure 3.2]. Bright CD4++/low 
SSC cells within the Panleucogate were then identified [gate C in Scatter plot 3 of Figure 
3.2] and using the FlowCOUNTTM bead population (identified as a single, very bright, 
tight population in the light scatter plot: Plot 1 of Figure 3.2), the absolute CD4+ cell count 
derived using the formula:  
(Total CD45+/CD4++ events) / (total number of beads acquired) x [number of 
beads/µl].  
Figure 3.2 illustrates an ideal result report of a sample analysed using the PLG-CD4 
method and protocol at the Johannesburg laboratory. The report includes relevant quality 
control steps (plots; 5-7 identified within a red box in Figure 3.2). Here, the light scatter 
plot is used to visualise the age and integrity of the sample. The CD45FITC vs. SSC scatter 
plot is used to distinguish all leucocytes and all CD45bright lymphocytes. The CD4PE vs. 
CD45FITC scatter plot is used to monitor colour compensation, the FL4 vs. Cell Size 
scatter plot is used to emunerate FlowCount beads and these used to monitor instrument 
performance and in the calculation of the absolute cells counts. The CD45FITC vs. 
Complexity scatter plot is used to identify debris (Gate G referred to as the Listgate) so that 
it is excluded from the listmode file. 
 
 
 
 
  
 32
 
Figure 3. 2: Figure to illustrate the derivation of CD4+ counts of Leucocytes and CD4% of 
Lymphocytes using the 2-colour PLG protocol on Beckman Coulter flow cytometers. 
3.3.2.4 Acquisition and Analysis of Samples using the MultiTEST/TruCount CD4 
Protocol 
The MultiTEST/TruCount (BDB) is a 4-colour method that uses TruCount tubes that have 
encased at their bottom a lyophilised bead pellet. The pellet is of a known bead 
concentration and is provided per tube lot by the manufacturer (BDB). It dissolves during 
sample preparation, releasing a known number of fluorescence beads which are gated 
during analysis and used as the reference population to determine the absolute cell counts. 
4-colour MS/TC (BDB) was the predicate CD4+ cell count method used at the CDC 
laboratory. The precision of MS/TC measurements is dependent on the single pipetting 
step of the sample. Reverse pipetting is reported to be the most reliable dispensing method 
for absolute cell count methodologies and is therefore the recommended technique for use 
in this sample pipetting step(64, 144). This dispensing technique was however not used by 
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the writer in performing the MS/TC method because the assessment of her pipetting skill 
showed that she had better pipetting precision using the forward pipetting technique. 
Acquisition and analysis were performed using the automated MultiSETTM software 
programme (BDB). A minimum of 5000 lymphocyte events (BDB defined threshold) were 
acquired for each sample and the un-gated data files for the samples saved.  
In analysis, the TruCount bead population (defined as high SSC and very bright 
fluorescence signal events), CD4+ and CD8+ populations (defined as CD3+4+ and CD3+8+ 
in accordance to the lymphocyte gating strategy: Plot of CD4APC versus CD8PE in Figure 
3.3), were automatically identified using in-built predefined AttractorTM regions in the 
MultiSETTM software. Absolute CD4+ cell counts were derived using the formula:  
([Number of CD3+/CD4+ events] / [Number of acquired bead events]) x ([Number of 
beads/pellet] / [Volume of blood (50µl) used]). 
Figure 3.3 shows a typical result report of a sample analysed using the 4-colour MS/TC 
method. 
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Figure 3. 3: Figure to illustrate the derivation of CD4+ counts and CD4% of Lymphocytes using the 
CD45bright Lymphocyte Gating Strategy in the 4-colour MultiTEST/TruCount protocol on a 
FACSCalibur flow cytometer. 
3.3.3 Daily Quality Control (QC) 
Daily internal quality control checks using CaliBRITETM beads (BDB) for the 
FACSCalibur and Flow-CHECKTM beads (BCI, Miami, FL) for the Epics XL and FC-500 
were performed, in accordance to manufacturer instructions to monitor the state of the 
respective flow cytometers. The beads have fluorescence properties and the ability to 
simulate unstained and stained cells and are used to assess laser linearity, check instrument 
sensitivity i.e. fluorescence settings, and to adjust fluorescence compensation, if required.  
A daily check of the sample preparation process for Beckman Coulter methods (2-colour 
PLG-CD4 and TetraONE) was also performed using stabilised blood controls i.e. the 
“Low” and “Normal” value ImmunotrolTM products (both, BCI, Miami, FL). The purpose 
of this check was to ensure the quality and state of the monoclonal antibody, and reagents 
used with the Multi Q-PrepTM system, for use with samples in the clinically relevant range 
(<200 cells/µl) and those with normal CD4+ counts. Verification of the sample preparation 
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process for the 4-colour MS/TC (BDB) methodology was not performed as such an 
equivalent product is not available from BDB.  
Samples were only analysed on the flow cytometers after calibration and performance 
checks had been performed and passed by the technicians at the respective laboratories.  
3.3.3.1 Procedure for Performing Daily QC for the FACSCalibur  
The FACSCalibur linearity and performance check was performed using freshly prepared 
CaliBRITETM beads (CaliBRITETM 3 and CaliBRITETM APC) (BDB). Levy-Jennings plots 
of the calibration results were automatically created and saved to facilitate day-to-day 
comparison of instrument performance and settings by the CDC laboratory technicians. 
Two falcon tubes were set-up: To one, filtered sheath (1ml) and a drop of well mixed 
unlabeled beads (BDB) and APC beads (BDB) were added. To the second tube, filtered 
sheath (3ml) and a drop of unlabeled beads, APC, FITC, PE and PerCP labeled beads 
(BDB) were added. The tubes are gently vortexed (5 seconds), placed within a carousel, 
loaded onto the FACSCalibur and FACSComp software (BDB) launched to perform the 
automated instrument check.  
If the calibration check passed, the new Lyse-No-Wash calibration settings were 
automatically set-up and used as the settings for sample acquisition. 
 
3.3.3.2 Procedure for Performing Daily QC for the EPICS-XL and FC-500 Flow 
Cytometers 
Although the Epics-XL and FC-500 Beckman Coulter flow cytometers are different 
models, the two were calibrated using a similar procedure and in accordance to the 
manufacturer’s instructions. In this study, the calibrating material was prepared once and 
used for both instruments i.e., used to calibrate the Epics-XL then used for the FC-500.  
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A test tube with FlowCHECKTM fluorescent beads (BCI, Miami, FL) (15 drops) was 
acquired on the flow cytometer for 10 seconds to check the optical alignment of the laser 
and stability of the fluidic system. This was followed by performing the bead 
reproducibility check, to verify the stability of the flow count rate and assess precision of 
instrument fluidics(152). The latter was assessed by examining the consistency in the 
number of beads acquired when 11 replicate preparations of FlowCOUNTTM beads (BCI, 
Miami, FL) (100µl) in sheath fluid (BCI, Miami, FL) (900µl) were each acquired for 120 
seconds. Lastly, a check to verify proper functioning of the sample preparation reagents 
and that of the Multi Q-PrepTM system was performed using stabilised blood controls 
(ImmunoTrolsTM, BCI, Miami, FL). The controls were samples of known CD4+ cell 
counts. One had a CD4+ cell count in the normal range and the other a low CD4+ cell 
count. These were prepared and analysed in a manner similar to that in which patient 
samples were processed when using the 4-colour TetraONE T-cell and 2-colour PLG-CD4 
methods. The quality of the reagents and proper function of the Multi Q-PrepTM were 
confirmed if derived absolute and percentage results for the controls were within the 
acceptable ranges provided by the manufacturer (BCI, Miami, FL). 
3.3.4 Gating Strategies 
The method of data analysis (gating strategy and choice of flow cytometric threshold) has 
been shown to influence accurate enumeration of CD4+ counts and to have an impact on 
the duration the sample testing period can be extended.  
Two standard gating strategies were used in the analysis of the flow data; the 2-colour 
PanLeucogating (PLG) strategy(39, 59) and the 4-colour Lymphocyte gating strategy 
(CD45bright Lymphocyte Gating) (62, 64). A comparison of CD4+ cell counts derived using 
both strategies was carried out to assess two aspects, (1) the impact of gating on bias 
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between different CD4 methods and systems and (2) which method was better able to 
extend the window period of testing.   
3.3.4.1 The PanLeucogating Strategy (PLG)  
The PLG is a strategy based on a combination of primary CD45 gating (i.e. CD45/Side 
Scatter [SSC]) and subsequent CD4 gating (i.e. CD4/SSC) [scatter plots enclosed in blue 
rectangle of Figure 3.4]. It typically uses Forward scatter [FSC] as a threshold (although 
CD45 fluorescence as a threshold is used in some instances with PLG, as in this study) and 
employs CD45/SSC to select (gate) all leucocytes [gate A in scatter plot 2 of Figure 3.4) as 
the primary reference population and subsequent CD4 expression and side scatter based on 
this total leucocyte gate, to define and enumerate absolute CD4+ cells [gate C in scatter 
plot 3 of Figure 3.4]. The use of CD4 expression and side scatter specifically excludes 
monocytes from the analysis and eliminates the need for CD3 to define lymphocytes(39, 
40, 59). The conventional lymphocyte based (CD45bright) gate is thus not applied for cell 
enumeration in PLG testing. However a CD4% of lymphocytes, as defined in the various 
international guidelines(62, 64, 94), can be obtained by incorporating CD45bright gating 
with PLG to define lymphocytes (CD45bright cells) [gate B of scatter plot 2 in Figure 3.4] 
and then, to assess the proportion of CD45bright lymphocytes that are CD4 bright/low SSC 
cells [gate D in scatter plot 4 of Figure 3.4].  
The 2-colour PLG gating strategy, as well as the CD4% of lymphocytes are illustrated in 
Figure 3.4.  
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Figure 3. 4: Figure to illustrate the 2-colour PanLeucogating Strategy as performed on the Beckman 
Coulter flow Cytometers 
Gate A (PLG Gate) showing total CD45 cells (leucocytes), Gate B is CD45bright lymphocyte gate and Gate C 
are the CD4+ T-cells gated on Gate A.    
 
Figure 3.5 following, shows how the writer re-analysed 4-colour MS/TC data files using 
the 2-colour PLG strategy on the FACSCalibur. 
 
 
 
 
 
 
 
Figure 3. 5: Figure to illustrate the concept of the PanLeucogating strategy as performed on the 
FACSCalibur. 
3.3.4.2 The Lymphocyte Gating Strategy (CD45bright Lymphocyte Gating) 
The lymphocyte gating strategy illustrated in Figure 3.6 differs from PLG in that it uses 
CD45 expression to define CD45bright expressing cells lymphocytes, and CD3 to exclude 
monocytes from the analysis and to define CD4+ T cells.  
This strategy typically identifies and uses the CD45bright (CD45++/low SSC) lymphocyte 
population from among leucocytes [gate A in scatter plot 1 of Figure 3.6] as the reference 
population. Then using a SSC/CD3 scatter plot gated on total leucocytes [gate B in scatter 
plot 2 of Figure 3.6], the T-lymphocyte cells (CD3+) are defined. CD3+4+ and CD3+8+ 
1.                                                2. Gated on total leucocytes            3. Gated on lymphocytes 
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absolute cell counts and percentages are then identified from the CD3+ population gated on 
CD45bright lymphocytes [Scatter plot 3 of Figure 3.6].  
The lymphocyte gating strategy is used in the 4-colour MultiTEST/TruCount protocol (BD 
Biosciences) and in the 4-colour TetraONE/FlowCount (BC, Miami, FL) protocol. 
 
 
 
1.  2.   3. Gated on B 
Gate A 
 
Gate B CD3 T Lymphocytes 
 
Figure 3. 6: Figure to illustrate the use of the CD45bright lymphocyte gating strategy as applied in the 4-
colour MS/TC CD4 protocol. 
3.4 Analyses performed to Assess Impact of CD4 Methodology 
including Specific Reagents, Flow Cytometry System, Protocol 
Setups and Gating on Bias of CD4 Reporting.  
3.4.1 Assessment of Bias introduced through Poor Precision of Pipetting 
The reliability of pipette measurements is dependant on proper calibration of pipettes and 
on an operator’s pipetting skill(144). There are two known techniques of pipetting; (i). The 
forward displacement technique, also called forward pipetting (FP) and (ii) the reverse 
pipetting technique (RP). A description of both of these is provided in Appendix B. 
Several pipettes were validated to enable the selection of properly functional pipettes for 
use in this study and to determine the precision of the operator (the writer) using the two 
pipetting techniques.  
3.4.1.1 Validation of Pipettes used in this Study (Johannesburg and CDC 
laboratories) 
In this process, the amount of distilled water repeatedly measured using a pre-set pipette 
was weighed, to ensure that the dispensed volume was precise and accurate (i.e. within the 
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range specified by the respective pipette manufacturer). The water pipetted, was weighed 
using weighing balances that had been calibrated and confirmed to be functionally suitable 
for use. Either 50µl or 100µl of water was pipetted depending on the pipette being 
validated and the volume of blood the pipette would be used to measure in the study 
assessments. This exercise was performed using the forward pipetting technique at the two 
laboratories.  
An empty plastic test tube (BC, Miami, FL) was weighed and the balance tared (made to 
read 0.00g). Distilled water (50µl or 100µl) was then pipetted into the weighed test tube, 
the tube placed back onto the balance and the weight of the water determined. This process 
was repeated 20 times for each pipette. The water measurements (weights) taken were then 
grouped into tens to calculate the overall mean weight (corresponding to the average 
volume of water pipetted), standard deviation and coefficient of variation (%CV: [standard 
deviation/mean] x 100 – a measure of precision) for each pipette. The pipettes (A, B and 
C) that had the best precision in the hands of the writer (i.e. the lowest %CV readings) 
were selected for use in this study. 
3.4.1.2 Operator Skill Assessment (Forward pipetting versus Reverse pipetting 
precision assessment of the operator [Intra-operator]) 
The purpose of validating pipettes and of evaluating the operator’s (MM) pipetting skill 
prior to carrying out the other assessments of the study was to minimise the influence due 
to pipette error on other variables studied. 
Using one of the validated pipettes [Pipette A, a fixed volume (100µl) pipette)], the two 
pipetting techniques, forward (FP) and reverse pipetting (RP) were assessed to determine 
the technique with which the operator (the writer), obtained better precision. Blood instead 
of distilled water was used in this exercise. The blood used was taken from routine CD4 
samples after they had been tested at either of the two laboratories. The tube of blood was 
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thoroughly mixed to ensure homogeneity each time blood was pipetted off (from the same 
sample). Twenty-two samples (2 per day) were used over 11 days. Repeat volumes of 
blood (100µl) pipetted using RP or FP were weighed, the weights grouped into sets of 10s, 
averaged and the precision documented. A  %CV was then determined in a manner similar 
to that done in the pipette validation exercise [section 3.4.1.1]. The technique (FP) with 
which the least variation was obtained (i.e. %CV<1) was chosen and used through out the 
study for all the methodologies including the 4-colour MultiTEST/TruCount method 
(BDB).  
Upon establishing the pipetting technique (FP) to be used, the operator’s (the writer) 
pipetting skill using the other two validated pipettes B and C, was also assessed. 
3.4.1.3 Within-Laboratory Pipetting Skills Precision Assessment (Precision between 
different operators measured separately at two different geographically 
located sites [Inter-Operator]) 
i) Within-laboratory (within and between operator) precision 
To assess the amount of variation that could result when different operators within the 
same laboratory processed the same patient sample, within-laboratory variability was 
determined. Ten laboratory technicians from each of the two laboratories were asked to 
participate in this assessment. Each technician’s precision was first assessed and thereafter, 
the overall precision of the respective laboratory established using the results of all ten 
participating operators. Samples with CD4+ cell counts (274 cells/µl and 267 cells/µl) in 
the clinically significant HIV range (≤ 200 cells/µl to ≤ 350 cells/µl) were used.  
At the Johannesburg laboratory, the blood sample was divided into 10 aliquots (1ml each) 
and each of the 10 operators given an aliquot to process ten times (stain with monoclonal 
antibody, fix and analyse) following the 4-colour TetraONE method. Each of the ten 
operators obtained 10 CD4+ cell count results and the mean, SD and %CV (precision of 
each operator) for each set was calculated. The laboratory %CV was then determined by 
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deriving the %CV of the hundred CD4+ counts obtained by the ten operators. This exercise 
was repeated by 10 technicians using the 4-colour MultiTEST/TruCount method on the 
FACSCalibur, at the CDC laboratory. 
ii) Cell count related variation (within-operator variability across strata of clinical 
CD4+ counts) 
The impact of an operator’s pipetting skill on the precision of CD4+ counts in different 
strata, derived using the same method of sample preparation and model of flow cytometer, 
was assessed by the writer at the Johannesburg laboratory and by a different operator (MR) 
at the CDC laboratory. Three blood samples were used in this exercise; one with a low cell 
count (< 200 cells/µl), an intermediate count (300-500 cells/µl) and a high CD4+ count (> 
500 cells/µl). This assessment was used to examine the precision of the two operators at 
the different CD4+ strata, especially at the clinically relevant range of < 200 cells/µl CD4+ 
counts.  
Testing was performed using the 4-colour MultiTEST/TruCount method. Although it is not 
the required pipetting method for this system and because the measurable outcome was 
assessment of precision (and not accuracy), the forward pippetting technique was used in 
this precision assessment because both operators mentioned above demonstrated better 
pipetting precision using FP than when using the recommended RP technique(64, 144). 
Each sample from the different strata mentioned above was processed 10 times by the 
same operator (MR, or the writer) at the respective CDC and Johannesburg laboratories. 
The prepared samples were subsequently acquired and analysed on the FACSCalibur at 
each site. Each set of ten CD4+ count results for each sample, at each site, were averaged, 
the SD determined and the %CV derived. The %CV value was then used to assess 
precision of the two operators at the respective laboratory.  
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3.4.2 Assessment of the Bias introduced through use of Different 
Manufacturer Sample Preparation Systems and the Same Gating 
Strategy (CD45bright Gating). 
Forty one samples that were on average <16 hours old, were analysed on the Epics-XL, 
FC-500 and the FACSCalibur flow cytometers at the Johannesburg laboratory.  Each 
sample was processed following both the Johannesburg’s TetraONE method and the BDB 
4-colour MultiTest/TruCount method. Samples prepared using the TetraONE method were 
analysed on the Epics-XL and the FC-500 instruments. Those samples prepared using the 
MultiTest/TruCount method were analysed on the FACSCalibur. Three CD4+ absolute 
count results were thus obtained for each sample for this part of the study. The mean 
absolute CD4+ counts from the respective flow cytometers were compared in order to 
assess the amount of bias introduced to CD4+ counts when samples were prepared using 
different manufacturer systems but applying the same gating strategy [i.e. 4-colour 
CD45bright lymphocyte gating: (1). 4-colour MS/TC on the FACSCalibur (BDB) versus 4-
colour TetraONE on the Epics XL (BC) and (2). 4-colour MS/TC on the FACSCalibur 
(BDB) versus 4-colour TetraONE on the FC-500 (BC)]. 
3.4.3 Assessment of the Bias introduced through use of Different 
Manufacturer Sample Preparation Systems including Application of 
Different Gating Strategies and Different Flow Cytometeric Threshold 
for Data Acquisition. 
The purpose of this exercise was to mimic the reality of laboratory to laboratory testing and 
determine the potential bias introduced between CD4+ counts from different laboratories 
when different manufacturer sample preparation systems including using different gating 
strategies (2-colour PLG versus the 4-colour CD45bright lymphocyte gating), are used in the 
determination of CD4+ cell counts. 
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Data of the 41 samples processed following the Johannesburg TetraONE protocol (in 
section 3.4.2) in which the 4-colour CD45bright lymphocyte gating strategy and 2-colour 
PLG strategy were performed as a single analysis on the same samples, was used. CD4+ 
cell counts derived using the 2-colour PLG gating strategy and counts originally obtained 
using the 4-colour MultiTEST/Trucount protocol on the FACSCalibur in section 3.4.2 
were compared [i.e. 4-colour MS/TC on the FACSCalibur (BDB) versus 2-colour PLG on 
the Epics XL (BC) and 4-colour MS/TC on the FACSCalibur (BDB) versus 2-colour PLG 
on the FC-500 (BC)]. 
3.4.4 Assessment of the Bias introduced when Samples are prepared using the 
Same Manufacturer System and Analysed on the Same Flow Cytometer 
but using a Different Gating Strategy.  
In this analysis, CD4+ counts derived using the 4-colour CD45bright lymphocyte gating 
strategy and counts of the same samples derived using the 2-colour PLG strategy on the 
same flow cytometer, were compared for each instrument [i.e. 4-colour CD45bright 
lymphocyte gating on the Epics XL (BC) versus 2-colour PLG gating on the Epics XL 
(BC) and 4-colour CD45bright lymphocyte gating on the FC-500 (BC) versus 2-colour PLG 
gating on the FC-500 (BC)]. Data of the 41 samples processed following the TetraONE 
protocol (in section 3.4.2) was used.  
This assessment of the potential impact of bias introduced by use of different gating 
strategies in the same manufacturer method was also performed for the BDB system. Here, 
the 20 samples drawn in new blood stabilisation tubes at the Johannesburg laboratory were 
processed following the 4-colour MS/TC method (BDB) and analysed on the FACSCalibur 
(BDB). Data files of these 20 samples were retrospectively re-analysed using the 2-colour 
PLG gating approach to derive MS/TC-PLG CD4+ counts. The respective 2-colour PLG 
and 4-colour MS/TC CD4+ counts were then compared to assess bias introduced through 
gating alone on the BDB system.  
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3.4.5 Assessment of the Bias introduced when Samples prepared using the 
Same Manufacturer System were Analysed on Different models of Flow 
Cytometers from the Same Manufacturer. 
In this analysis, an assessment was made of the bias that could potentially be introduced if 
different cytometers from the same manufacturer (Beckman Coulter) were used to derive a 
CD4+ cell count from the same prepared sample (the same prepared sample was re-run on 
a different model of flow cytometer from the same manufacturer). The cytometers are 
individually calibrated since there is typically no standardisation of instrument calibration.  
Here, the writer used data of 61 samples that had been routinely processed by the 
technicians at the Johannesburg laboratory for CD4+ counts using the 2-colour PLG-CD4 
protocol. Two thirds (45) of the 61 samples selected had CD4+ counts < 350 cells/µl so 
that bias in readings for this clinically significant range could be examined. The samples 
(N=61), were analysed on the Epics XL (XL-2) and immediately re-analysed on the 
FC-500 cytometer (by the laboratory scientist) and the absolute CD4+ cell counts from the 
two instruments compared [i.e. 2-colour PLG-CD4 (BC) on the Epics XL (BC) versus 2-
colour PLG-CD4 (BC) on the FC-500 (BC)]. 
In addition, data of the 41 samples processed following the TetraONE protocol in Section 
3.4.2, was also used. CD4+ cell counts derived using 4-colour CD45bright lymphocyte 
gating on the Epics XL (BC) were compared to counts derived using 4-colour CD45bright 
lymphocyte gating on the FC-500 (BC). Similarly, the CD4+ cell counts derived using 2-
colour PLG gating on the Epics XL (BC) were compared to counts derived using 2-colour 
PLG gating on the FC-500 (BC). 
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3.5 Analyses performed to Assess Impact of Logistical Factors 
including Time from Venesection, handling during Transportation 
and Temperature on Bias of CD4+ Reporting. 
The purpose of this exercise was to assess whether time, temperature and continuous 
motion affected the integrity of whole blood samples and thus, the precision of CD4+ cell 
counting.  
Thirty two samples (average age between ≥12-24 hours old) were analysed using the 4-
colour TetraONE protocol at the Johannesburg laboratory and 55 samples (average age < 6 
hours old) were analysed using the 4-colour MS/TC protocol at the CDC laboratory for this 
exercise.  
i) Samples were processed on the day they were received for baseline (day of draw) 
CD4+ cell counts and then each sample split into four (850µl) aliquots. One aliquot 
was stored at refrigerator temperature (FT), another at room temperature (RT) and the 
third at 37ºC in a water bath. The fourth aliquot was kept in motion on a mixer at RT. 
The choice to split samples into aliquots of 850mls (or 4 equal aliquots depending on 
the volume of the sample received) was based on the average ‘fill’ of 5ml EDTA 
samples received in the Johannesburg laboratory and the requirement of the study to 
test each aliquot up to 8 days post venesection. Each aliquot was processed and 
analysed for a CD4+ cell count every day, for a period of 8 days from the day of draw 
(unfortunately, there was only sufficient sample to analyse all 32 samples received at 
the Johannesburg laboratory up to Day 5). Refrigerator temperature was noted to be 4-
6ºC in the Johannesburg laboratory and between 4.0-5.2ºC in the CDC laboratory. 
Room temperature was controlled and maintained by use of air-conditioners at both 
sites and ranged between 17-23ºC in Johannesburg and 20-23ºC at the CDC laboratory. 
Specimens kept at FT and water-bath temperatures were allowed to equilibrate to room 
temperature (30 minutes) before they were processed on days (1-8) of follow-up.  
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A comparison of mean CD4+ cell counts at baseline and mean CD4+ cell counts on 
each of days (1-8) for samples stored at the different temperatures (FT, RT and 37ºC) 
and those subjected to continuous motion, was done for each laboratory. Clinical 
significance of the CD4+ count results was assessed for two scenarios:  
 When the similarity between the mean baseline count (Day 0) and mean day 
counts was > 90% or ≥ 95% and 
 When the mean difference from baseline (BL) was defined as < 40 cells/µl or ≤ 
20 cells/µl.  
Two cutoffs were used in each scenario, one stricter than the other, so as to effectively 
determine the duration testing could be extended without compromising the quality of 
CD4 results. 
The days of storage at which the similarity between day and baseline counts (mean 
difference) was more (less) than the above specified values, were accepted as the days to 
which samples could still be analysed for reliable results at each laboratory.  
To further examine sample integrity, corresponding changes in CD4 percentages 
(CD4%) were also examined. For this, clinical significance was defined as the 95% 
confidence intervals outside the range of (>95 - <105).  
ii) In order to assess if the type of gating strategy used influenced the precision of CD4+ 
counting and specifically, whether use of the simpler gating strategy (2-colour PLG) 
could extend the window of testing and analysis, CD4+ counts (N=32) derived using 
the two different gating strategies (4-colour CD45bright lymphocyte gating strategy and 
2-colour PLG strategy), were also compared. The mean change in CD4+ cell counts 
derived using the TetraONE protocol with 4-colour CD45bright lymphocyte gating and 
the mean change of counts derived using 2-colour PLG stategy (i.e. 2-colour PLG 
TetraONE analysed data) were compared to determine which gating strategy was more 
reliable for analysis of aged samples.  
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3.6 Evaluation of the use of a Commercial Whole Blood Stabilising 
Agent to enable Extending the Window of CD4 Testing. 
This aspect of the study was carried out to investigate the use of a stabiliser in maintaining 
the integrity of samples during transportation and the ability of the stabiliser to extend the 
window of CD4 testing beyond current expectations. 
 New (BDB) (2ml) CD4 blood collection tubes, specifically manufactured to address the 
challenges associated with transporting of whole blood specimens, were used. These 
collection tubes contained a  stabiliser (Streck Laboratories, Omaha, NE) that was meant to 
preserve the integrity of leucocyte surface antigenic sites and thus improve reliability of 
CD4+ testing up to seven days if specimens were kept at room temperature (18-30°C) and 
up to three days if specimens are kept at 37°C. 
In this study, the effect of extending the period of testing beyond that recommended by the 
manufacturer was also evaluated.  
A total of 89 samples were tested following the 4-colour MS/TC method. This included 69 
of the 89 samples analysed in Uganda and 20 samples analysed at the Johannesburg 
laboratory. In Johannesburg, all 20 samples were freshly bled and were on average < 2 
hours old at the time of delivery to the laboratory. The 69 samples analysed at the CDC 
laboratory were all > 24 hours old at the time of delivery to the laboratory. These samples 
were drawn from patients in a CDC study cohort approximately 400 km away and were 
delivered to the laboratory in the afternoon of the following day. 
Samples received at the Johannesburg laboratory were analysed for baseline (Day 0) CD4+ 
cell counts and the remaining blood stored at room temperature (17–23° C) for follow-up 
CD4+ cell counts on days 6, 7 and 8. The writer did not do the actual CD4+ testing for this 
assessment at the CDC laboratory as this had already been done by the laboratory (the 100 
tubes provided by BDB for the evaluation had all been used by the time she returned to 
Uganda). Here, the samples were processed and analysed by three technicians depending 
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on the technicians on duty. Baseline CD4+ counts were measured a day after venesection 
(i.e. Day 1, considered as baseline) and subsequent CD4+ counts derived on days 4, 6 and 
eight from the day of venesection.  
3.7 Statistics 
All statistical analysis was performed with the help of Professor Piet Becker, a statistian 
from the Medical Research Council in South Africa. The CD4+ absolute count data were 
analysed using Microsoft Excel and Stata Statistical Software (StataCorp. 2003. Stata 
Statistical Software: Release 8.0. College Station, TX: Stata Corporation). Data from the 
two laboratories were analysed individually. Statistical methods used included Spearman’s 
correlation, a paired-t-test and two-way analysis of variance. Box and Whisker plots of 
absolute CD4+ counts were also plotted to assess variation in CD4+ counts over time from 
the day of blood draw. Bland Altman comparisons were used to assess agreement between 
CD4+ cell counts at baseline to eight days after draw (days 1-8). The mean absolute 
difference (bias) between the day readings and the 95% limits of agreement (LOA = mean 
difference ± 2 standard deviations) as well as, day to baseline mean CD4+ count ratios and 
confidence intervals, were calculated. P values < 0.05 were considered significant. 
  
 50
4.0 RESULTS 
4.1 Analyses performed to Assess Impact of CD4 Methodology 
Including Specific Reagents, Flow Cytometry System, Protocol 
Setups and Gating on Bias of CD4 Reporting. 
4.1.1 Assessment of Bias introduced through Poor Precision Pipetting  
4.1.1.1 Validation of pipettes used in this study (Johannesburg and CDC 
Laboratories) 
Three pipettes (A, B and C) were validated for use in this study: Pipette (A) was a fixed 
volume pipette (100µl) that was used at the Johannesburg (WITS) laboratory to measure 
blood (100µl) and fluorescence beads (100µl) required for the 4-colour TetraONE method. 
Pipette (B) a (200µl) volume pipette was validated and used to measure blood (50µl) 
required for the 4-colour MS/TC method, used at the CDC laboratory. Pipette (C) a (20 - 
200µl) volume pipette was validated and used to measure (50µl) and (100µl) required 
respectively for the 4-colour MS/TC and TetraONE CD4 testing methods performed at the 
Johannesburg laboratory. A summary of the mean volumes of distilled water measured and 
(%CV) obtained for each of these pipettes, selected for use in this study, is shown in Table 
(4.1) below. 
Table 4. 1: Summary of the mean volumes of water and %CVs obtained for the pipettes selected for 
use in this study 
Forward Pipetting Forward Pipetting 
Laboratory Pipette N Set to Measure 
Mean Volume (µl) Range (µl) Mean %CV 
Johannesburg A 20 100µl 100.30 99.3-100.8 0.390 
  C 20 50µl 49.95 48.8-50.5 0.705 
  C 20 100µl 101.65 101.0-102.2 0.370 
CDC B 20 50µl 50.30 49.6-50.9 0.650 
N: Represents the number of replicate measurements performed to assess the precision of each respective 
pipette. 
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4.1.1.2 Operator skill assessment (Forward Pipetting versus Reverse pipetting 
precision assessment of the operator [Intra-operator]) 
The pipetting skill of the operator/writer was assessed to determine the technique i.e. 
reverse pipetting (RP) or forward pipetting (FP), with which she obtained better precision. 
Figure 4.1 shows the development and improvement of the operator’s (the writer) pipetting 
skill with time. Greater precision of blood measurements (measured as the coefficient of 
variation [%CV]) was obtained when the FP technique was used, with the %CV declining 
from 0.912% to 0.387% over 11 days. An average %CV of (0.513%) was demonstrated 
with FP compared to (1.214%) with the RP technique. FP was therefore chosen as the 
technique for use in all pipetting procedures used by the operator/writer in this study.  
Demonstration of the  O perator Pipetting Skill using 
the Fixed Volume Eppendorf Pipette  (Pipette  A).
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Figure 4. 1: A Figure Demonstrating the Improvement of an Operator’s Pipetting Skill over Time. 
 
Table (4.2) summarises the volumes measured and %CVs obtained by the operator using 
the FP technique with pipette A, B, and C. 
Table 4. 2: Summary of the mean blood volumes and % CVs obtained for the pipettes used in the study 
Forward Pipetting Forward Pipetting 
Laboratory Pipette N Set to Measure 
Range (µl) Mean Volume (µl) Mean %CV Range (%CV) 
Johannesburg A 98 100µl 93.5-100.4 96.6 0.513 0.387-0.912 
  C 30 50µl 47.7-50.3 48.7 0.804 0.647-0.985 
  C 30 100µl 93.3-99.2 95.9 0.670 0.570-0.902 
CDC B 91 50µl 44.1-52.8 48.3 1.153 0.844-1.911 
N: represents the number of replicate sets performed for each pipette. 
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4.1.1.3 Within-laboratory pipetting skills precision assessment (Precision between 
different operators measured separately at two different geographically 
located sites [Inter-operator])  
i) Within-laboratory (within and between operator) precision. 
A mean laboratory CD4+ count of 261cells/µl, range (225 – 293 cells/µl) was obtained 
when replicate CD4+ counts of the same patient sample were derived by ten different 
operators at the Johannesburg laboratory and a mean of 261cells/µl range (217 – 318 
cells/µl) was obtained for the sample that was analysed by 10 technicians at the CDC 
laboratory.  
Each operator’s coefficient of variation was calculated using the 10 replicate CD4+ counts 
they each derived for the sample. Figure 4.2 shows the precision of the individual operators 
at the two laboratories. A mean laboratory %CV of (4.75%), with the individual %CV 
ranging from (2.51% – 6.20%) was obtained for the 10 operators at the Johannesburg 
laboratory, and a mean %CV of (7.5%), ranging from (3.61% - 9.28%) for the individual 
operators, obtained at the CDC laboratory. Overall, precision was better between the 10 
participating technologists at the Johannesburg laboratory i.e. within-laboratory precision 
was better. 
 
Figure 4. 2: Precision of different operators in two different laboratories using samples with low CD4+ 
Counts 
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ii) Cell count related variation (within-operator variability across strata of clinical 
CD4+ counts). 
As expected, the assessment of within-operator variability (the writer’s) at the 
Johannesburg laboratory showed that less precision (highest variation) in replicate CD4+ 
cell counts was noted in the sample that had a low CD4+ count; with a %CV of (8.46%) 
and (4.95%) after adjusting for an outlier reading caused by a pipetting error. Also as 
expected, better precision (%CV = 2.92%) was observed for CD4+ counts of the sample 
with a medium count (300-500cells/µl) and the least variation (%CV = 2.83%) was 
observed in CD4+ counts of the sample with a high CD4+ count (> 600cells/µl).  
At the CDC laboratory where this assessment was carried out by a different operator, the 
highest variability was again observed in replicate CD4+ counts of the sample with a low 
CD4+ count [%CV = (9.19%), and (6.44%) after adjusting for an outlier reading most 
probably caused by a pipetting error too]. Less variation (5.41%) was observed in CD4+ 
counts of the sample with a high CD4+ count and the least variation (%CV = 5.20%) 
observed for the sample with the medium CD4+ count. Overall, greater precision of 
measurements was demonstrated by the operator/writer in Johannesburg using the FP 
technique. 
4.1.2 Assessment of the Bias introduced when Samples prepared using the 
Same Manufacturer System were Analysed on the Different Models of 
Flow Cytometers from the Same Manufacturer. 
The aim of this part of the study was to assess the contribution made by platform alone to 
bias in CD4 reporting (sample preparation, protocol set-up and gating strategy were 
identical and instruments were from the same manufacturer but different models of flow 
cytometers were used).  
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Two sets of data were also used in this analysis. In the first, CD4+ counts of 61 samples 
processed using the 2-colour PLG-CD4 method and analysed on the Epic-XL then 
immediately re-analysed using the same protocol on the FC-500, were compared.  
The second data set used was that of the 41 samples analysed using the TetraONE protocol 
in which a 4-colour CD45bright lymphocyte gated and 2-colour PLG gated CD4+ count 
were obtained simultaneously in a single analysis on the same sample. All samples were 
first analysed on the Epic-XL and thereafter, immediately re-analysed on the FC-500. 
Significant differences were observed between the CD4+ counts of all three comparisons 
confirming that the two instruments/models from the same manufacturer (BC) showed 
intrinsic differences and could therefore not be used interchangeably for generating CD4+ 
counts . A summary of the results of this assessment are shown in Table 4.3. 
A slightly higher correlation between CD4+ counts derived on the different models of 
instruments was obtained for the data set of the 41 samples which were processed by a 
single operator (the writer) [rho = 0.9909; mean difference = -15.24 cells/µl and rho = 
0.9873; mean difference = -22.27 cells/µl] than for the CD4+ counts of the 61 samples that 
were processed by different operators [rho = 0.9597; mean difference = -39.20 cells/µl]. 
Table 4. 3: Assessment of variation between CD4+ Counts derived using the same system, protocol set-
up and gating strategies but on different models of flow cytometers from the same manufacturer 
Gating Strategies/Instruments CD4 Range N Mean Diff (cells/µl) 95% CI LOA p-value rho 
2-colour PLG on Epics-XL vs.  
2-colour PLG on FC-500  
10 - 1009 61 -39.20§ (-52.13, -26.27) [61.98, -139.98] <0.0001 0.9597 
CD45bright gating on Epics-XL 
vs. 
CD45bright gating on FC-500 
32 - 906 41 -15.24* (-21.8, -8.7) [26.02, -56.50] <0.0001 0.9909 
2-colour PLG on Epics-XL vs. 
2-colour PLG on FC-500  
34 - 928 41 -22.27* (-29.0, -15.5) [20.45, -64.99] <0.0001 0.9873 
 Abbreviations: Mean Diff - Mean difference in CD4+ count between instruments; 95% CI - 95% 
Confidence Intervals for the mean difference; LOA - Limits of agreement; p-value - for the mean difference. 
* Single operator; § Several operators. 
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4.1.3 Assessment of the Bias introduced when Samples are prepared using the 
same Manufacturer System and Analysed on the same Flow Cytometer 
but using a Different Gating Strategy. 
The aim of this part of the study was to assess the contribution made by gating alone to 
bias in CD4 reporting (all other known variables were identical including sample 
preparation, instrument settings and data acquisition). Two data sets were used in this 
analysis. In the first set, the CD4+ counts of 41 samples derived using the TetraONE 
protocol to generate both a 4-colour CD45bright lymphocyte gated CD4+ count  and a 2-
colour PLG count in a single analysis on the Epics-XL (BC) and then on the FC-500 (BC), 
were compared for each instrument (i.e. 4-colour CD45bright lymphocyte gated CD4+ 
counts  vs. 2-colour PLG gated counts on the Epics-XL;  4-colour CD45bright lymphocyte 
gated CD4+ counts  vs. 2-colour PLG gated counts on the FC-500). The second data set 
comprised of the baseline CD4+ counts of the 20 samples drawn at the Johannesburg 
laboratory in the new special 2ml blood stabilisation tubes and processed following the 4-
colour MS/TC protocol on the FACSCalibur. Listmode data files of these latter analyses 
were retrospectively re-analysed using a 2-colour PLG gating strategy. The results of these 
two sets of analyses are shown in Table 4.4. 
Table 4. 4: Assessment of variation between CD4 counts derived using the same CD4 method but 
different gating strategies on the same instrument. 
Instrument Protocols N CD4 Range 
Mean Diff 
(cells/µl) 95% CI LOA p-value rho 
Epics XL 
4-colour CD45bright –  
2-colour PLG 41 35 - 860 -7.12 (-10.14, -4.11) [11.98, -26.22] <0.0001 0.9979 
FC-500 
4-colour CD45bright –  
2-colour PLG 41 32 - 928 -14.15 (-17.79, -10.50) [8.96, -37.26] <0.0001 0.9957 
FACSCalibur 
4-colour MS/TC – 
 2-colour PLG 20 54 - 774 -9.80 (-15.33, -4.27) [13.84, -33.44] 0.0015 0.9925 
Abbreviations: Mean Diff - Mean difference in CD4+ count between instruments; 95% CI - 95% 
Confidence Intervals for the mean difference; LOA - Limits of agreement; p-value - for the mean difference. 
 
Although the mean difference of CD4+ counts between these two gating strategies was 
statistically significant [i.e. (–7.12 cells/µl, p = <0.0001) on the Epics-XL; (–14.15 cells/µl,  
p = <0.0001) on the FC-500 and (-9.8 cells/µl, p = 0.0015) on the FACSCalibur], it would 
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not be clinically significant and can be interpreted to mean a constant but tight (small) 
difference between the two gating strategies. 
Determination of the intra-class correlation coefficient indicated that the derived CD4+ 
counts were highly correlated; rho = 0.9979 between the two gating strategies on the Epics-
XL; rho = 0.9957 on the FC-500 and rho = 0.9925 on the FACSCalibur. 
4.1.4 Assessment of the Bias introduced through use of Different 
Manufacturer Sample Preparation Systems and Applying the Same 
Gating Strategy (CD45bright Gating).  
The aim of this part of the study was to mimic a real-life situation where two laboratories 
using completely different systems for CD4 preparation but similar gating strategies, can 
result in bias/differences of CD4 reporting. In this analysis, the mean CD4+ counts of 41 
samples processed following the 4-colour TetraONE protocol on both the Epics–XL and 
FC-500 flow cytometers, and the 4-colour MS/TC protocol on the FACSCalibur, were 
compared (observations summarised in Table 4.5). The CD4+ count range was (35 – 843 
cells/µl) on the Epics-XL, (32 – 906 cells/µl) on the FC-500 and (36 – 770 cells/µl) on the 
FACSCalibur. CD4+ counts derived on the FACSCalibur were closer to counts derived on 
the Epics-XL than to CD4+ counts derived using the FC-500. 
Table 4. 5: Assessment of bias (Bland Altman analysis) in CD4+ counts derived using different 
protocols that use a similar gating strategy (CD45bright lymphocyte gating) and different 
manufacturers’ flow cytometers. 
Instruments CD4 Range N Mean Diff (cells/µl) 95% CI LOA p-value rho 
FACSCalibur - 
Epics XL 35 - 843 41 -2.59 (-13.3, 8.1) [65.03, -70.21] 0.6271 0.9831 
FACSCalibur  - 
FC500 32 - 906 41 -17.83 (-28.3, -7.4) [48.17, -83.83] 0.0013 0.9806 
Abbreviations: Mean Diff - Mean difference in CD4 counts between instruments; 95% CI - 95% Confidence 
Intervals for the mean difference; LOA - Limits of agreement; p-value - for the mean difference. 
 
Bland-Altman analysis showed the mean difference in count and 95% confidence intervals 
between the FACSCalibur using 4-colour MS/TC and Epics-XL using the 4-colour 
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TetraONE protocol to be (–2.59[CI; -13.3, 8.1] and the limits of agreement (LOA) (65.03, 
-70.21). This difference was not significant (p = 0.6271).  
However, the mean difference between the same patient CD4+ counts derived using the 4-
colour MS/TC on the FACSCalibur and using the 4-colour TetraONE on the FC-500 (bias 
= -17.83 cells/µl) was significantly different from zero (p = 0.0013) implying that these 
two instruments could not be used interchangeably for reporting CD4 counts in the same 
laboratory. 
As expected, because all instruments essentially measured the same parameter viz. CD4+ 
counts, determination of the intra-class correlation coefficient (rho), demonstrated a high 
correlation of the CD4+ counts between the different protocols performed on different flow 
cytometers; rho = 0.9831 between CD4+ counts derived using the 4-colour MS/TC on the 
FACSCalibur and the 4-colour TetraONE on the Epics-XL, and rho = 0.9806 between 
CD4+ counts derived using the 4-colour MS/TC on the FACSCalibur and the 4-colour 
TetraONE protocol on the FC-500. 
4.1.5 Assessment of the Bias introduced through use of Different 
Manufacturer Sample Preparation Systems including Application of 
Different Gating Strategies and Different Flow Cytometeric Threshold 
for Data Acquisition. 
The aim of this part of the study was to mimic a real-life situation where two laboratories 
using completely different systems for CD4 reporting but participating in the same network 
to support the same treatment programme, can result in differences in CD4 reporting and 
hence influence patient management according to CD4 method used. In this assessment, 41 
CD4 results generated using the 4-colour MS/TC (BDB) were compared to CD4+ counts 
derived using the 2-colour PLG (BC) protocol on both the Epic-XL and FC-500 flow 
cytometers [see section 4.1.4]. A CD4+ count range of (35 – 860 cells/µl) was noted on the 
Epics-XL, a range of (34 – 928 cells/µl) noted on the FC-500 and a range of (36 – 770 
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cells/µl) noted on the FACSCalibur.  The CD4+ counts derived on the FACSCalibur were 
again closer to counts derived on the Epics-XL than to CD4+ counts derived using the FC-
500. Table 4.6 shows the results of this analysis.  
Table 4. 6: Assessment of bias (Bland Altman analysis) of CD4+ counts derived using different 
manufacturers’ flow cytometers, preparation systems and gating strategies: BC PLG versus BDB 
CD45bright gated MS/TC. 
Instruments CD4 Range N Mean Diff (cells/µl) 95% CI LOA p-value rho 
FACSCalibur - 
Epics XL 35 - 860 41 -9.71 (-19.8, 0.41) [54.41, -73.83] 0.0596 0.9838 
FACSCalibur  - 
FC500 34 - 928 41 -31.98 (-44.1, -19.9) [44.60, -108.56] <0.0001 0.9665 
Abbreviations: Mean Diff - Mean difference in CD4+ count between instruments; 95% CI - 95% 
Confidence Intervals for the mean difference; LOA - Limits of agreement; p-value - for the mean difference. 
 
Bland-Altman analysis showed the mean difference in CD4+ count and 95% confidence 
intervals between the FACSCalibur using 4-colour MS/TC and Epics-XL using 2-colour 
PLG gating to be (–9.71[CI; -19.83, 0.41]) and the LOA (54.41, -73.83). The difference in 
CD4+ counts between these two machines showed borderline statistical significance (p = 
0.0596). Use of these two different gating strategies appears to have slightly increased the 
bias between the two methods i.e., from a mean bias of -2.59 cells/µl or -17.83 cells/µl 
when both systems employed a CD45bright gating strategy (Table 4.5), to a mean bias of -
9.71 cells/µl or -31.98 cells/µl when different gating strategies (either CD45bright or PLG) 
were used. However, this increase in bias could also be a reflection of differences in the 
flow cytometric acquisition and analysis. 
CD4+ counts derived using 4-colour MS/TC on the FACSCalibur and counts derived using 
2-colour PLG gating on the FC-500 were significantly different (p <0.0001) implying that 
these two different manufacturer sample preparation systems with different gating 
strategies, should not be used interchangeably for analysis of the same samples.   
The correlation between 4-colour and 2-colour PLG CD4+ counts from the FACSCalibur 
and the FC-500 respectively was slightly lower (rho = 0.9665) than that observed when 
both systems employed  a CD45bright gating. However, once again, the correlation between 
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CD4+ counts derived using the 4-colour MS/TC on FACSCalibur and the 2-colour PLG on 
the Epics-XL was high (rho= 0.9838). 
4.2 Analyses performed to Assess Impact of Logistical Factors 
including Time from Venesection, handling during Transportation 
and Temperature on Bias of CD4+ Reporting. 
There are several factors that can affect the integrity of a sample prior to it getting to the 
laboratory for testing. These include the temperature at which the sample is stored or held, 
motion of the sample (typically during transportation of the sample to the laboratory) and 
time from venesection.  The effect of these three factors was assessed using 32 samples 
processed following the 4–colour TetraONE method at the Johannesburg laboratory and 
using 55 samples processed following the 4–colour MS/TC method at the CDC laboratory. 
A single CD4 method was used at each site to enable meaningful assessment of impact of 
either motion, temperature or time from venesection on precision of CD4 counting. 
4.2.1 Assessing the effect of Motion on Whole Blood Sample Integrity.  
Samples were kept in motion on a blood mixer or rocker to mimic a situation were samples 
may be damaged (haemolysed) during transit in a vehicle to a laboratory.  
Table (4.7) below summarises the CD4+ count results of the samples analysed using the 4-
colour TetraONE protocol at the Johannesburg laboratory.  
The mean absolute CD4+ count of the 32 samples analysed at 12-24 hours from 
venesection (baseline reading) was 306 cells/µl and the range (13 – 1237 cells/µl) but this 
dropped to a mean of 205 cells/µl, range (5 – 961 cells/µl) by Day 5.  
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Table 4. 7: Summary of the mean change in CD4+ counts of samples kept in motion and derived using 
the 4-colour TetraONE protocol at the Johannesburg laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 Count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline (~1) 12-24 32 13 - 1237 306 223.56  
≥1-2 36-48 31 12 - 1133 284 209.44 (702.88, -134.88) 
≥2-3 60-72 32 14 - 1152 273 211.92 (696.84, -150.84) 
≥3-4 84-96 32 9 - 1000 249 192.38 (633.76, -135.76) 
≥4-5 108-120 32 7 - 936 213 174.67 (562.34, -136.34) 
≥5-6 132-144 32 5 - 961 205 174.25 (553.5, -143.50) 
≥6-7 156-168 28* 6 - 952 194 181.34 (556.68, -168.68) 
≥7-8 180-192 21* 4 - 786 169 171.01 (511.02, -173.02) 
≥8-9 204-216 5* 3 - 592 164 243.83 (651.66, -323.66) 
 * Lack of sufficient aliquot volumes for testing resulted in fewer numbers of samples available for testing 
after the Day 5 reading (> than 132 hours); the number of samples that could be statistically analysed 
reduced to 28, 21 and to 5 on testing days ≥6-7, ≥7-8 and ≥8-9 respectively (EDTA tubes are typically only 
filled with between 3ml and 5ml of blood). The aliquot volumes made were dependent on the original patient 
sample volumes venesected and sent to the laboratory. If a small sample volume had been sent, a small 
aliquot (< 850µl) was all that could be obtained which restricted the number of times for re-testing. 
 
Table (4.8) below shows details of how long samples kept in motion on a rocker at room 
temperature (17 – 23ºC) could be kept before preparation and analysis (Johannesburg 
laboratory). When the >90% integrity limit was applied, samples could be used to derive 
precise and accurate CD4+ counts for up to 48 hours from venesection (only 1 day from 
receipt into the laboratory and up to 2 days from venesection, p = 0.0015). However, when 
the >95% limit (p = 0.4557) or the mean difference limit of <40 cells/µl (p = 0.2453), or 
the limit of <20 cells/µl (p = 0.7642) were applied, samples could not be used beyond 24 
hours from venesection or the day of receipt in the laboratory. Beyond these specified 
days, CD4+ counts were significantly different from baseline counts (i.e. p > 0.05) 
suggesting that sample handling and motion could affect the sample integrity. 
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Table 4. 8: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline for 
samples kept in motion and derived using the 4-colour TetraONE protocol 
p value* at 
Cut-off p value** at Cut-off Day post 
venesection 
Ratio of Mean 
Day CD4 Count 
to Baseline as a 
(%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
≥1-2 95.18 8.96 0.0015 0.4557 30.22 79.32 (1.6, 58.8) 0.2453 0.7642 
≥2-3 89.04 9.35 0.717 0.9995 32.69 34.12 (20.4, 45.0) 0.1172 0.9782 
≥3-4 80.85 16.67 0.998 1 56.97 65.27 (33.4, 80.5) 0.9242 0.9983 
≥4-5 68.15 13.61 1 1 92.53 70.38 (67.2, 117.9) 0.9999 1 
≥5-6 64.82 15.19 1 1 100.88 73.13 (74.5, 127.2) 1 1 
≥6-7 64.97 45.49 0.9964 0.9992 131.27 229.41 (45.6, 216.9) 0.9812 0.9936 
≥7-8 51.44 14.99 1 1 145.95 109.63 (96.1, 195.9) 0.9999 1 
≥8-9 46.96 15.80 0.9982 0.9988 169.4 269.06 (-164.7, 503.5) 0.8286 0.8589 
Clinical significance was defined as values > 0.05. When the p value is significant i.e. < 0.05, accept H1 i.e. 
observed CD4 ratio exceeds 90% or 95 % and thus the associated day of storage is still acceptable; 
SD - Standard Deviation; CI – 95% Confidence Interval. 
* Ho: CD4 Ratio = 90% (95%) versus H1: CD4 Ratio > 90% (95%) 
** Ho: the Mean difference in CD4+ counts = 40 cells/µl (20cells/µl) versus H1: Mean difference in CD4 + 
counts is < 40cells/µl (20cells/µl). 
 
Corresponding CD4% values (data in Table 4.9) showed that samples could be reliably 
analysed up to 72 hours from venesection (or 2 days from receipt in the laboratory) [95% 
CI = (98.6, 104.8)]. 
Table 4. 9: Change in mean CD4% as a ratio of baseline over days for samples kept in motion and 
derived using the 4-colour TetraONE protocol 
Day post  
venesection 
Age of samples  
(hours) 
Ratio of Mean CD4% to 
Baseline as a (%) SD 95% CI p value 
≥1-2 36-48 100.08 5.99 (97.9, 102.3) <0.0001 
≥2-3 60-72 101.72 8.58 (98.6, 104.8) 0.0001 
≥3-4 84-96 107.16 12.77 (102.6, 111.8) <0.0001 
≥4-5 108-120 123.39 26.62 (113.8, 133.0) <0.0001 
≥5-6 132-144 143.97 90.19 (111.5, 176.5) 0.0022 
≥6-7 156-168 150.52 89.54 (115.8, 185.2) 0.0014 
≥7-8 180-192 170.69 117.51 (115.7, 225.7) 0.0048 
≥8-9 204-216 450.26 608.72 (-518.4, 1418.9) 0.1637 
 
Further analysis was performed to assess whether use of the simplified 2-colour PLG 
gating strategy could extend the window of testing noted above (in samples that had been 
subjected to ongoing motion). No difference in time to testing was observed between the 
gating strategies except when the <40 cells/µl limit was applied (data shown in Appendix 
C). The 2-colour PLG gating strategy increased the window of testing to 72 hours from 
venesection (2 days from time of receipt of the samples into the laboratory or 3 days from 
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venesection) (p = 0.0443). This effect was however not observed when corresponding 
CD4% values were analysed. Merging of the CD45bright population with nearby monocytes 
resulted in the samples not being suitable for use beyond 1 day from receipt into the 
laboratory (or 48 hours from venesection) [95% CI = (99.9, 104.2)] (data shown in 
Appendix C). 
The following figure (4.3) shows the deterioration in sample integrity over 8 days of 
follow-up of a sample kept in in motion at the Johannesburg laboratory. 
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Figure 4. 3: A figure illustrating the deterioration in sample integrity over time for a sample kept in 
motion and derived using the 2-colour PLG protocol (Sample #31 was chosen as it included the least 
amount of fluorescent debris in the PLG gate). 
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Table (4.10) shows the changes in the CD4+ counts of the 55 samples that were kept in 
motion on a mixer and were analysed using the 4-colour MS/TC protocol (CDC 
laboratory). All 55 samples analysed at baseline had sufficient volumes for follow-up on 
all 8 days. A mean CD4+ count of 344 cells/µl, ranging from (17 – 814 cells/µl) was 
obtained at baseline and a mean of 205 cells/µl, range (11 – 634 cells/µl) obtained by Day 
8. 
Table 4. 10: Summary of the mean change in CD4+ counts of samples kept in motion and derived using 
the MS/TC protocol at the CDC laboratory 
Day post 
venesection 
Age of samples  
(hours) 
No. of  
Samples 
CD4 Count 
Range 
Mean CD4 
Count 
  
SD 
  
LOA 
Baseline <6 55 17 - 814 344 195.51  
1 24 55 13 - 854 337 198.83 (734.66, -60.66) 
2 48 55 12 - 792 312 182.98 (677.96, -53.96) 
3 72 55 13 - 697 302 167.99 (637.98, -33.98) 
4 96 55 15 - 672 287 167.66 (622.32, -48.32) 
5 120 55 16 - 673 273 160.55 (594.10, -48.10) 
6 144 55 13 - 672 256 161.99 (579.98, -67.98) 
7 168 55 9 - 724 235 150.37 (535.74, -65.74) 
8 192 55 11 - 634 205 145.96 (496.92, -86.92) 
 
Table 4.11 summarises the results obtained using the 4-colour MS/TC protocol. These 
were similar to those obtained at the Johannesburg laboratory. Samples could only be used 
to derive precise and accurate CD4+ counts for up to 24 hours (only 1 day from receipt into 
the laboratory) when the >90% integrity limit was used and only on the day of receipt into 
the laboratory if the >95% integrity limit was applied. Samples could however still be 
analysed by day 1 (p < 0.0001) when the <40cells/µl limit and the <20cells/µl limit were 
applied (p = 0.0158). 
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Table 4. 11: Change in mean CD4 counts as a ratio of baseline and mean difference to baseline for 
samples kept in motion, and derived using the 4-colour MS/TC protocol 
p value at Cut-
off p value at Cut-off Day post 
venesection 
Ratio of Mean 
Day CD4 Count 
to Baseline as a 
(%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
1 97.66 12.63 <0.0001 0.0623 6.25 46.20 (-6.2, 18.8) <0.0001 0.0158 
2 90.53 11.57 0.3688 0.9971 31.40 43.38 (19.7, 43.1) 0.0737 0.9717 
3 89.65 13.55 0.5766 0.9975 41.18 50.83 (27.4, 54.9) 0.5681 0.9984 
4 83.58 12.85 0.9997 1 56.80 53.75 (42.3, 71.3) 0.9879 1 
5 80.02 14.32 1 1 70.38 64.75 (52.9, 87.9) 0.9995 1 
6 74.26 17.16 1 1 87.60 79.16 (66.2, 109.0) 1 1 
7 67.90 16.18 1 1 108.82 89.46 (84.6, 133.0) 1 1 
8 58.26 16.93 1 1 138.20 97.87 (111.7, 164.7) 1 1 
 
Corresponding CD4% values (Table 4.12) showed that sample integrity had deteriorated 
by day 1 and that samples could therefore not be analysed beyond the day of receipt into 
the laboratory. 
Table 4. 12: Change in mean CD4% as a ratio of baseline over days for samples kept in motion and 
derived using the MS/TC protocol 
Day of  
venesection 
Age of  samples 
(hours) 
No of 
Samples 
Ratio of Mean CD4%  
 to Baseline as a (%) SD 95% CI p-value 
1 24 55 102.71 9.12 (100.3, 105.2) <0.0001 
2 48 55 105.13 11.16 (102.1, 108.2) <0.0001 
3 72 55 107.58 12.07 (104.3, 110.8) <0.0001 
4 96 55 108.25 12.44 (104.9, 111.6) <0.0001 
5 120 55 112.66 14.24 (108.8, 116.5) <0.0001 
6 144 55 113.32 16.65 (108.8, 117.8) <0.0001 
7 168 55 116.76 18.86 (111.7, 121.9) <0.0001 
8 192 55 117.12 20.54 (111.6, 122.7) <0.0001 
 
Figure 4.4 shows the deterioration in sample integrity over 8 days of follow-up of a sample 
kept in in motion at the CDC laboratory. 
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Figure 4. 4: A figure illustrating the deterioration in sample integrity over time for a sample kept in 
motion and analysed using the 4-colour MS/TC Protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
Merging of CD3+ 
and CD3- 
populations 
CD3+CD4+ 
lymphocytes 
Merging of dim  
CD4+ monocytes and 
CD45++ lymphocytes 
Baseline 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7 
Day 8 
  
 67
Figure 4.5 and 4.6 below, show the changes in CD4+ counts over time for blood samples 
kept in motion at the two laboratories.  
 
Figure 4. 5: Change in CD4+ Counts as a ratio of baseline over days for samples kept in motion and 
derived using the 4-colour TetraONE protocol at the Johannesburg Laboratory or using 4-colour 
MS/TC at the CDC laboratory 
Legend: Horizontal line at 90 – shows the sample Integrity Limit set at 90% similarity of Day reading to 
Baseline.Days labeled 1-8 for Johannesburg laboratory have actual estimated respective ages of ≥1-2, 
≥2-3, ≥3-4, ≥4-5, ≥5-6, ≥6-7, ≥7-8 and ≥8-9 days.  
 
 
Figure 4. 6: Mean difference in CD4+ Counts to baseline over days for samples kept in motion and 
derived using the 4-colour TetraONE protocol at the Johannesburg Laboratory or using the 4-colour 
MS/TC at the CDC Laboratory 
Legend: Horizontal line at 40 – shows the sample Integrity Limit set at a mean difference of 40cells/µl 
between day and baseline readings. Days labeled 1-8 for Johannesburg laboratory have actual estimated 
respective ages of ≥1-2, ≥2-3, ≥3-4, ≥4-5, ≥5-6, ≥6-7, ≥7-8 and ≥8-9 days. 
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A fast decline in mean CD4+ counts over the 8 days from baseline was observed of the 
samples analysed at both laboratories. The difference in the rate of sample disintegration at 
the two laboratories may have been caused by the difference in the age of the samples used 
and how the samples were kept in motion. Samples analysed at the Johannesburg 
laboratory were older at baseline (about 12-24 hours old versus 6 hours old samples used at 
the CDC laboratory) and possibly disintegrated faster since they had been kept in motion 
on a rocker which movement was more vigorous than if a mixer had been used. 
  
4.2.2 Assessing the effect of Temperature on Whole Blood Sample Integrity. 
4.2.2.1 Storage of Blood Samples at 37°C in a Water Bath 
In order to assess the effect warmer temperatures could have on the integrity of blood, 
samples were kept at 37°C in a water bath to mimic ambient temperatures in some African 
countries. 
Tables 4.13 and 4.14 provide an overview of CD4+ count results derived using the 4-
colour TetraONE protocol at the Johannesburg laboratory. Flow cytometric analyses of 
samples kept in a water bath at 37ºC showed that sample integrity had deteriorated 
significantly a day after baseline. Blood samples were clearly hemolysed by day 2 and 
follow-up was discontinued on day 3 in order to prevent unnecessary blockages in the flow 
cytometer that could result from analysing markedly disintegrated samples.  
Table 4. 13: Summary of the mean change in CD4+ counts of samples kept at 37°C in a water bath and 
derived using the 4-colour TetraONE protocol at the Johannesburg laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 Count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline (~1) 12-24 32 13 - 1237 306 223.56  
≥1-2 36-48 31 18 - 1043 237 190.42 (617.84, -143.84) 
≥2-3 60-72 30 5 - 590 214 126.46 (466.92, -38.92) 
≥3-4 84-96 23 5 - 468 125 95.82 (316.64, -66.64) 
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Table 4. 14: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline for 
samples kept at 37°C in a water bath and derived using the 4-colour TetraONE protocol 
p value at 
Cut-off p value at Cut-off Day post  
venesection 
Ratio of Mean 
Day CD4Count 
to Baseline as a 
(%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
≥1-2 79.36 16.80 0.9993 1 76.16 81.27 (46.9, 105.5) 0.9914 0.9998 
≥2-3 73.53 17.40 1 1 100.77 117.76 (57.6, 144.0) 0.9963 0.9997 
≥3-4 48 24.45 1 1 175.5 168.36 (107.5, 243.5) 0.9998 1 
 
Significant differences from baseline CD4+ counts were observed as early as Day 1 (within 
24 hours from venesection). Similar observations were made when CD4 % values were 
used (Table 4.15) and when the data was analysed using the 2-colour PLG gating strategy 
(data shown in Appendix D). 
Table 4. 15: Change in mean CD4% as a ratio of baseline over days for samples kept at 37°C and 
derived using the 4-colour TetraONE protocol 
Day post  
venesection 
Age of samples  
(hours) 
No of 
Samples 
Ratio of mean CD4% to 
Baseline as a (%) SD 95% CI p value 
≥1-2 36-48 31 103.54 12.31 (99.0, 108.1) 0.0003 
≥2-3 60-72 30 93.10 18.43 (86.2, 100.0) 0.07119 
≥3-4 84-96 23 130.23 42.24 (112.0, 148.5) 0.0003 
 
Figure 4.7 shows the deterioration in sample integrity over 8 days of follow-up of a sample 
kept in a Water Bath at 37°C. 
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Figure 4. 7: A figure illustrating the deterioration of sample integrity over time for a sample kept in a 
water bath at 37°C and derived using the 2-colour PLG protocol (sample #31 was chosen as it included 
the least amount of fluorescent debris in the PLG gate). 
 
Table 4.16 below gives an overview of the results obtained for the 55 samples kept at 37°C 
in a water bath at the CDC laboratory. 
Similar to observations made at the Johannesburg laboratory, samples kept at this 
temperature were hemolysed by day 2 so follow-up was discontinued. 
Table 4. 16: Change in mean CD4+ counts of samples kept in a water bath at 37°C and derived using 
the 4-colour MS/TC protocol at the CDC laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 Count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline <6 55 17 - 814 344 195.51  
1 24 55 11 - 704 298 179.40 (656.80, -60.80) 
2 48 55 4 - 538 195 137.61 (470.22, -80.22) 
 
Table 4.17 shows the CD4 count results for samples analysed following the 4-colour 
MS/TC protocol. These results were similar to those obtained using the 4-colour TetraONE 
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protocol. Samples kept at 37°C could not be used for accurate enumeration of CD4+ counts 
at all. On the contrary however, corresponding CD4% values (Table 4.18) showed that 
samples could still be analysed after being kept for a day at 37°C [95% CI = (98.0, 103.7)].  
 
Table 4. 17: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline for 
samples kept at 37°C in a water bath and derived using the MS/TC protocol 
p value at  
Cut-off p value at Cut-off Day post 
venesection 
Ratio of Mean 
Day CD4 count 
to Baseline as a 
(%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
1 84.29 13.26 0.9988 1.0000 45.38 42.96 (33.8, 57.0) 0.8215 1.0000 
2 52.52 15.61  1.0000 1.0000 148.67 79.39 (127.2, 170.1) 1.0000 1.0000 
 
Table 4. 18: Change in mean CD4% as a ratio of baseline over days for samples kept at 37°C in a 
water bath and derived using the MS/TC protocol 
Day post  
venesection 
Age of  samples 
(hours) 
No of 
Samples 
Ratio of Mean CD4%  
to Baseline as a (%) SD 95% CI p-value 
1 24 55 100.89 10.52 (98.0, 103.7) 0.0001 
2 48 55 91.7 21.47 (85.9, 97.6) 0.8702 
 
Figure 4.8 shows the deterioration in sample integrity over 8 days of follow-up of a sample 
kept in a Water Bath at 37°C. 
  
 72
 
Figure 4. 8: A figure illustrating the deterioration in sample integrity over time for a sample kept in a 
water bath at 37°C and derived using the 4-colour MS/TC protocol 
 
Figures 4.9 and 4.10 show the changes in CD4+ counts over time for blood samples kept at 
37ºC at the two laboratories. 
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Figure 4. 9: Change in CD4+ counts as a ratio of baseline over days for samples stored at 37°C in a 
water bath and derived using the 4-colour TetraONE protocol at the Johannesburg Laboratory or 
using 4-colour MS/TC at the CDC laboratory 
Legend: Horizontal line at 90 – shows the sample Integrity Limit set at 90% similarity of Day reading to 
Baseline.Days 1-3 for Johannesburg laboratory have actual estimated respective ages of ≥1-2, ≥2-3 and 
≥3-4 days. 
 
 
Figure 4. 10: Mean difference in CD4 Counts to Baseline over Days for samples stored at 37°C in a 
Water Bath and derived using the 4-colour TetraONE protocol at the Johannesburg Laboratory or 
using the 4-colour MS/TC at the CDC Laboratory 
Legend: Horizontal line at 40 – shows the sample Integrity Limit set at a mean difference of 40 cells/µl 
between day and  Baseline readings. Days 1-3 for Johannesburg laboratory have actual estimated 
respective ages of ≥1-2, ≥2-3 and ≥3-4 days. 
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4.2.2.2 Storage of Blood Samples at Room Temperature 
Room temperature (RT) varies and is dependent on geographical location/region. To assess 
the effect different temperatures could have on sample integrity, samples were kept at RT 
and followed up for 8 days. RT was controlled and maintained within a specific range 
[between 17 - 23°C at the Johannesburg laboratory and between 20 - 23°C at the CDC 
laboratory] by use of air conditioners.  
 
Tables (4.19) and (4.20) summarise the results obtained when CD4+ count data was 
analysed using the 4-colour TetraONE protocol at the Johannesburg laboratory. The mean 
absolute CD4+ count of the 32 samples analysed at baseline decreased at a slower rate than 
was observed when the samples were stored at a higher temperature (37°C): The mean 
CD4+ count was 306 cells/µl, range (13 – 1237 cells/µl) at baseline (average age of 
samples ≥12-24 hours old) and 266 cells/µl, range (10 – 1154 cells/µl) by Day 5 (average 
age of samples ≥132-144 hours old).  
Table 4. 19: Summary of the mean change in CD4+ counts of samples kept at room temperature (17-
23°C) and derived using the 4-colour TetraONE protocol at the Johannesburg laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 Count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline (~1) 12-24 32 13 - 1237 306 223.56  
≥1-2 36-48 31 16 - 1249 293 235.16 (763.32, -177.32) 
≥2-3 60-72 32 12 - 1195 285 216.56 (718.12, -148.12) 
≥3-4 84-96 32 10 - 1162 272 212.16 (696.32, -152.32)  
≥4-5 108-120 32 9 - 1024 259 195.02 (649.04, -131.04) 
≥5-6 132-144 32 10 - 1154 266 207.92 (681.84, -149.84) 
≥6-7 156-168 29* 10 - 846 243 177.71 (598.42, -112.42) 
≥7-8 180-192 23* 9 - 1059 236 218.89 (673.78, -201.78) 
≥8-9 204-216 5* 15 - 967 323 379.55 (1082.10, -436.1) 
* Lack of sufficient aliquot volumes for testing resulted in fewer numbers of samples available for testing 
after the Day 5 reading; the number of samples that could be statistically analysed reduced to 29, 23 and to 5 
on testing days ≥6-7, ≥7-8 and ≥8-9 respectively. 
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Table 4. 20: Change in mean CD4+ count as a ratio of baseline and mean difference to baseline over 
days for samples stored at room temperature (17-23°C) and derived using the 4-colour TetraONE 
protocol 
p value at Cut-
off p value at Cut-off  Day post  
venesection 
Ratio of Mean Day 
CD4 count to 
Baseline as a 
 (%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
≥1-2 97.44 12.26 0.001 0.1388 22 86.95 (-9.4, 53.4) 0.1253 0.5513 
≥2-3 92.99 9.28 0.0395 0.8865 20.91 19.28 (13.9, 27.9) <0.0000 0.6039 
≥3-4 87.25 10.20 0.9313 0.9999 33.78 31.23 (22.5, 45.0) 0.1343 0.991 
≥4-5 82.62 11.40 0.9995 1 46.53 40.94 (31.8, 61.3) 0.8131 0.9995 
≥5-6 84.85 10.26 0.996 1 40.16 30.82 (29,0, 51.3) 0.5113 0.9996 
≥6-7 79.97 11.25 1 1 75.9 91.67 (42.3, 109.5) 0.9814 0.999 
≥7-8 77.11 15.10 1 1 70.17 75.51 (38.3, 102.1) 0.9687 1 
≥8-9 82.66 20.18 0.7692 0.8784 92.20 103.60 (-36.4, 220.8) 0.8386 0.9029 
 
Significant differences in CD4+ counts were observed by day 3 implying that samples 
could only be analysed up 72 hours (2 days from time of receipt into the laboratory) when 
the >90% limit was applied (p = 0.9313) and within 24 hours from venesection (on the day 
of receipt into the laboratory) when the >95% limit (p = 0.1388) and the two mean 
difference limits were each applied. Corresponding CD4% data shown in Table 4.21 below 
also showed that accurate results were obtainable only up to 72 hours (2 days from receipt 
into the laboratory and up to 3 days from the time of venesection).  
Table 4. 21: Change in mean CD4% as a ratio of baseline over days for samples stored at room 
temperature (17-23°C) and derived using the 4-colour TetraONE protocol 
Day post  
venesection 
Age of samples 
(hours) 
No of 
Samples 
Ratio of Mean CD4% to  
 Baseline as a (%) SD 95% CI p value 
≥1-2 36-48 31 100.79 6.34 (98.5, 103.1) <0.0001 
≥2-3 60-72 32 102.06 5.58 (100.1, 104.1) <0.0001 
≥3-4 84-96 32 102.57 8.20 (99.6, 105.5) <0.0001 
≥4-5 108-120 32 106.09 13.36 (101.3, 110.9) <0.0001 
≥5-6 132-144 32 107.81 11.98 (103.5, 112.1) <0.0001 
≥6-7 156-168 30 109.66 15.22 (104.0, 115.4) <0.0001 
≥7-8 180-192 23 108.31 15.6 (101.6, 115.1) 0.0002 
≥8-9 204-216 5 125.07 1978 (100.5, 149.6) 0.0136 
 
No difference in the time to testing was observed when the data was analysed using the 2-
colour PLG gating strategy if the >90% or >95% or the <20 cells/µl mean difference limit, 
were each applied. However, this simplified gating strategy was able to extend the window 
of testing to 96 hours (3 days from time of receipt of the samples in the laboratory or 4 
  
 76
days from venection), when the <40 cells/µl cutoff was applied (data shown in Appendix 
E). This effect though, was not observed with the corresponding CD4% data. Merging of 
the CD45bright population with nearby monocytes resulted in the samples not being suitable 
for use beyond 48 hours (1 day from receipt into the laboratory and up to 2 days from the 
time of venesection) (data shown in Appendix E).  
Figure 4.11 shows the deterioration in sample integrity over 8 days of follow-up of a 
sample kept at RT. 
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Figure 4. 11: A figure illustrating the deterioration of sample integrity over time for a sample kept at 
room temperature (17-23°C) and derived using the 2-colour PLG protocol (sample #31 was chosen as it 
included the least amount of fluorescent debris in the PLG gate). 
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Tables (4.22) and (4.23) summarise the results for the 55 samples analysed using the 4-
colour MS/TC protocol at the CDC laboratory. 
Table 4. 22: Summary of the mean change in CD4+ counts of samples kept at room temperature (20-
23°C) and derived using the 4-colour MS/TC protocol at the CDC laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline <6 55 17 - 814 344 195.51  
1 24 55 16 - 779 337 192.77 (722.54, -48.54) 
2 48 55 13 - 774 325 188.98 (702.96, -52.96) 
3 72 55 14 - 850 331 190.45 (711.90, -49.90) 
4 96 55 14 - 776 300 171.54 (643.08, -43.08) 
5 120 55 18 - 718 295 165.26 (625.52, -35.52) 
6 144 55 11 - 679 279 169.16 (617.32, -59.32) 
7 168 55 13 - 717 253 156.61 (566.22, -60.22) 
8 192 55 15 - 571 224 149.77 (523.54, -75.54) 
 
Table 4. 23: Change in mean CD4+ count as a ratio of baseline and mean difference to baseline for 
samples stored at room temperature (20-23°C) and derived using the 4-colour MS/TC protocol 
p value at Cut-
off p value at Cut-off Day post 
venesection 
Ratio of Mean 
CD4 count 
to Baseline as 
a (%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
1 98.33 8.22 <0.0001 0.0020 6.09 28.44 (-1.6, 13.8) <0.0001 0.0003 
2 94.13 13.19 0.0119 0.6857 18.29 37.99 (8.0, 28.6) <0.0001 0.3700 
3 96.09 12.76 0.0004 0.2648 12.87 44.89 (0.7, 25.0) <0.0001 0.1221 
4 88.85 13.62 0.7326 1 43.07 54.47 (28.4, 57.8) 0.6613 0.9986 
5 87.56 12.40 0.9252 1 48.47 56.3 (33.3, 63.7) 0.8654 0.9998 
6 79.92 16.27 1 1 64.40 61.29 (47.8, 81.0) 0.9977 1 
7 73.24 16.07 1 1 90.60 80.61 (68.8, 112.4) 1 1 
8 63.70 16.84 1 1 119.16 89.78 (94.9, 143.4) 1.00 1.00 
 
Samples could not be analysed beyond 72 hours (day 3 from venesection) when the >90% 
cutoff limit (p = 0.7326) or the mean difference limit of <40 cells/µl were each applied (p 
<0.6613). However when the more strict limits (>95% and the mean difference limit of 
<20 cells/µl) were each applied, significant differences in CD4+ counts were observed 48 
hours from venesection (by day 2). Significant differences from baseline counts were also 
observed by day 2 [95% CI: (100.1, 105.20)] when corresponding CD4% values were used 
(data shown in Table 4.24). 
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Table 4. 24: Change in mean CD4% as a ratio of baseline over days for samples stored at room 
temperature (20-23°C) and derived using the MS/TC protocol 
Day post  
venesection 
Age of  samples 
(hours) 
No of 
Samples 
Ratio of Mean CD4%  
 to Baseline as a (%) SD 95% CI p-value 
1 24 55 102.4 7.70 (100.3, 104.5) <0.0001 
2 48 55 102.7 9.45 (100.1,105.2) <0.0001 
3 72 55 103.3 9.21 (100.8, 105.8) <0.0001 
4 96 55 103.2 11.99 (99.9, 106.4) <0.0001 
5 120 55 107.0 11.21 (103.9, 110.0) <0.0001 
6 144 55 105.5 15.65 (101.3, 109.7) <0.0001 
7 168 55 104.1 15.15 (100.0, 108.2) <0.0001 
8 192 55 103.4 15.75 (99.2, 107.7) 0.0001 
 
Figure 4.12 shows the deterioration in sample integrity over 8 days of follow-up of a 
sample kept at RT and derived using the 4-colour MS/TC protocol. 
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Figure 4. 12: A figure illustrating the deterioration in sample integrity over time for a sample kept at 
room temperature (20-23°C) and derived using the 4-colour MS/TC protocol 
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Changes over time in mean absolute CD4+ counts of samples stored at room temperature 
at the two laboratories are shown in Figures 4.13 and 4.14. A slightly faster decline in 
mean CD4+ counts over the eight days from baseline was again observed of the older 
samples (≥ 12-24 hours at baseline) analysed at the Johannesburg laboratory. 
 
Figure 4. 13: Change in mean CD4+ counts as a ratio of baseline over days for samples stored at room 
temperature and analysed using the 4-colour TetraONE protocol at the Johannesburg Laboratory or 
using the 4-colour MS/TC at the CDC Laboratory. 
Legend: Horizontal line at 90 – shows the sample Integrity Limit set at 90% similarity of Day reading to 
Baseline. Days labeled 1-8 for Johannesburg laboratory have actual estimated respective ages of ≥1-2, 
≥2-3, ≥3-4, ≥4-5, ≥5-6, ≥6-7, ≥7-8 and ≥8-9 days.   
 
 
 
Figure 4. 14: Mean difference in CD4+ Counts to Baseline over Days for samples stored at Room 
Temperature and derived using the 4-colour TetraONE protocol at the Johannesburg Laboratory or 
using 4-colour MS/TC at the CDC Laboratory. 
Legend: Horizontal line at 40 – shows the sample Integrity Limit set at a mean difference of 40cells/µl 
between day and baseline readings. Days labeled 1-8 for Johannesburg laboratory have actual estimated 
respective ages of ≥1-2, ≥2-3, ≥3-4, ≥4-5, ≥5-6, ≥6-7, ≥7-8 and ≥8-9 days. 
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4.2.2.3 Storage of Blood Samples at Refrigerator Temperature 
Table (4.25) below summarises the results obtained when CD4+ count data for the 32 
samples kept at 4-6°C at the Johannesburg laboratory were analysed using the 4-colour 
TetraONE protocol. The mean absolute CD4+ count of the 32 samples analysed at baseline 
was 306 cells/µl and the range (13 – 1237 cells/µl) but this dropped to a mean of 232 
cells/µl, range (12 – 951 cells/µl) by Day 5. Only 29, 22 and 9 of the 32 samples had 
sufficient volumes for sample preparation and analysis on days 6, 7 and 8 respectively.  
Table 4. 25: CD4+ count results of samples kept at refrigerator temperature (4–5°C) and derived using 
the 4-colour TetraONE protocol 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
samples 
CD4 count 
range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline (~1) 12-24 32 13 - 1237 306 223.56  
≥1-2 36-48 31 13 - 1199 287 216.72 (720.44, -146.44) 
≥2-3 60-72 32 12 - 1141 279 209.03 (697.06, -139.06) 
≥3-4 84-96 32 12 - 841 245 164.38 (573.76, -83.76) 
≥4-5 108-120 32 13 - 905 238 180.97 (599.94, -123.94) 
≥5-6 132-144 32 12 - 951 232 179.80 (591.60, -127.60) 
≥6-7 156-168 29 9 - 1033 215 203.56 (622.12, -192.12) 
≥7-8 180-192 22 9 - 497 176 140.97 (457.94, -105.94) 
≥8-9 204-216 9 6 - 171 87 58.83 (204.66, -30.66) 
 
Table (4.26) shows the details of how long samples stored at refrigerator temperature (4-
6°C) could be kept before preparation and analysis (Johannesburg laboratory).  
When the >90% integrity limit was applied, samples could be used to derive precise and 
accurate CD4+ counts for up to 48 hours (only 1 day from receipt into the laboratory and 
up to 2 days from the time of venesection (p = 0.0002). However, when the >95% limit (p 
= 0.2447), or the mean difference limit of <40 cells/µl (p = 0.1887) or that of <20 cells/µl 
(p = 0.7050) were applied, samples could not be used beyond 24 hours from venesection or 
the day of receipt in the laboratory.  
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Table 4. 26: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline for 
samples stored at refrigerator temperature and derived using the 4-colour TetraONE protocol 
p value at Cut-
off p value at Cut-off Day post  
venesection 
Ratio of Mean 
CD4 count to 
to Baseline as a 
(%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
≥1-2 96.06 8.39 0.0002 0.2447 27.56 78.57 (-0.8, 55.9) 0.1887 0.7050 
≥2-3 91.01 9.44 0.2742 0.9884 26.94 30.25 (16.0, 37.9) 0.0102 0.8979 
≥3-4 82.07 10.66 0.9999 1 60.25 72.90 (34.0, 86.5) 0.9369 0.9981 
≥4-5 77.22 11.91 1 1 67.28 62.89 (44.6, 90.0) 0.99 0.9999 
≥5-6 76.49 14.80 1 1 73.28 64.66 (50.0, 96.6) 0.9967 1 
≥6-7 66.94 13.18 1 1 104.90 78.47 (76.1, 133.7) 1 1 
≥7-8 59.94 17.79 1 1 129.82 151.27 (62.8, 196.9) 0.9945 0.9987 
≥8-9 58.97 19.13 0.9994 0.9998 65.89 65.69 (15.4, 116.4) 0.8645 0.9653 
 
Corresponding CD4% results (Table 4.27) showed that samples could be reliably analysed 
up to 72 hours from time of venesection (2 days from the day of receipt in the laboratory) 
[95% CI = (96.2, 101.7)]. 
Table 4. 27: Change in mean CD4% as a ratio of baseline over days for samples stored at refrigerator 
temperature and derived using the 4-colour TetraONE protocol 
Day post  
venesection 
Age of samples 
(hours) 
No of 
Samples 
Ratio of Mean CD4% to  
 Baseline as a (%) SD 95% CI p value 
≥1-2 36-48 31 97.78 5.56 (95.7, 99.8) 0.0046 
≥2-3 60-72 32 98.94 7.54 (96.2, 101.7) 0.003 
≥3-4 84-96 32 95.69 8.25 (92.7, 98.7) 0.319 
≥4-5 108-120 32 92.46 13.42 (87.6, 97.3) 0.8541 
≥5-6 132-144 32 99.62 25.48 (90.4, 108.8) 0.1564 
≥6-7 156-168 29 96.55 10.94 (92.4, 100.7) 0.2263 
≥7-8 180-192 22 100.07 14.18 (93.8, 106.4) 0.0541 
≥8-9 204-216 9 93.99 9.64 (86.6, 101.4) 0.6194 
 
When the TetraONE data was analysed using the 2-colour PLG gating strategy (data 
shown in Appendix F), this method of analysis was able to extend the window of testing to 
72 hours (2 days from receipt into the laboratory and up to 3 days from the time of 
venesection (p = 0.0277) when the >90% integrity limit or the mean difference limit of <40 
cells/µl, was applied. The 2-colour PLG strategy was also able to extend the window of 
testing to 48 hours (1 day from receipt into the laboratory and 2 days from the time of 
venesection) when the mean difference limit of <20 cells/µl was applied.  It however had 
no impact when the >95% integrity limit was applied. Samples could not be used beyond 
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the day of draw. Corresponding PLG CD4% values showed that samples could be analysed 
for up to 96 hours (3 days from receipt into the laboratory or 4 days from the time of 
venesection) (data is shown in Appendix F).  
Figure 4.15 shows the deterioration in sample integrity over 8 days of follow-up of a 
sample kept at FT at the Johannesburg laboratory. 
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Figure 4. 15: A figure illustrating the deterioration of sample integrity over time for a sample kept at 
refrigerator temperature (4-6°C) and derived using the 2-colour PLG protocol (sample #31 was chosen 
as it included the least amount of fluorescent debris in the PLG gate). 
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Table (4.28) describes CD4+ count results for samples kept at 4.0–5.2°C and analysed 
using the 4-colour MS/TC protocol at the CDC laboratory. All 55 samples analysed at 
baseline were followed up for the 8 days. A mean CD4+ count of 344 cells/µl, ranging 
from (17 – 814 cells/µl) was obtained at baseline and a mean of 301 cells/µl, range (14 – 
692 cells/µl) obtained by Day 8. 
Table 4. 28: CD4+ count results of samples kept at refrigerator temperature (4.0–5.2°C) and derived 
using the 4-colour MS/TC Protocol at the CDC laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 Count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline <6 55 17 - 814 344 195.51  
1 24 55 15 - 811 329 188.07 (705.14, 47.14) 
2 48 55 15 - 836 331 192.31 (715.62, -53.62) 
3 72 55 15 - 843 327 187.04 (701.08, -47.08) 
4 96 55 20 - 858 325 187.47 (699.94, -49.94) 
5 120 55 14 - 825 316 185.87 (687.74, -55.74) 
6 144 55 16 - 782 322 187.53 (697.06, -53.06) 
7 168 55 14 - 769 313 180.16 (673.32, -47.32) 
8 192 55 14 - 692 301 170.21 (641.42, -39.42) 
 
Reliable CD4+ counts were obtained up to Day 6 (samples <144 hours old) (p = 0.0119) 
when the >90% integrity limit was applied and only on the day of receipt of the samples to 
the laboratory when the >95% limit was applied. A similar trend was observed when the 
<40 cells/µl (p = 0.0014) and <20 cells/µl (p = 0.1763) mean difference limits were each 
applied. These results are shown in the following table (4.29). 
 
Table 4. 29: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline over 
days for samples stored at refrigerator temperature (4.0–5.2°C) at the CDC laboratory 
p value at Cut-
off p value at Cut-off Day post 
venesection 
Ratio of Mean 
CD4 count to 
Baseline as a 
 (%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
1 96.27 11.01 <0.0001 0.1983 14.76 41.41 (3.6, 26.0) <0.0001 0.1763 
2 96.52 12.32 0.0001 0.1825 12.58 40.18 (1.7, 23.4) <0.0001 0.0883 
3 95.86 12.91 0.0007 0.3125 16.93 47.69 (4.0, 29.8) 0.0004 0.3174 
4 95.43 9.64 0.0001 0.3714 18.46 35.33 (8.9, 28.0) <0.0001 0.3734 
5 92.11 9.61 0.0549 0.9852 27.09 32.47 (18.3, 35.9) 0.0024 0.9444 
6 93.52 11.23 0.0119 0.8329 21.87 43.08 (10.2, 33.5) 0.0014 0.6258 
7 91.08 12.42 0.2601 0.9885 30.94 47.68 (18.1, 43.8) 0.0824 0.9528 
8 88.11 8.62 0.9449 1 42.6 42.53 (31.1, 54.1) 0.674 0.9999 
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Corresponding CD4% values (Table 4.30) showed that reliable results could still be 
obtained up to 8 days from the day of venesection, [95% CI = (97.3, 102.4)]. 
 
Table 4. 30: Change in mean CD4% as a ratio of baseline over days for samples stored at refrigerator 
temperature (4.0–5.2°C) at the CDC laboratory 
Day post  
venesection 
Age of  samples 
(hours) 
No of 
Samples 
Ratio of Mean CD4%  
 to Baseline as a (%) SD 95% CI p-value 
1 24 55 100.38 10.11 (97.6, 103.1) 0.0001 
2 48 55 100.84 9.20 (98.4, 103.3) <0.0001 
3 72 55 101.65 10.33 (98.9, 104.4) <0.0001 
4 96 55 101.31 9.80 (98.7, 104.0) <0.0001 
5 120 55 100.85 9.09 (98.4, 103.3) <0.0001 
6 144 55 101.05 11.07 (98.1, 104.0) 0.0001 
7 168 55 99.79 11.76 (96.6, 103.0) 0.0019 
8 192 55 99.85 9.31 (97.3, 102.4) 0.0002 
 
Figure 4.16 shows the deterioration in sample integrity over 8 days of follow-up of a 
sample kept at refrigerator temperature and analysed using the 4-colour MS/TC protocol. 
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Figure 4. 16: A figure illustrating the deterioration of sample integrity over time for a sample kept at 
refrigerator temperature (4.0–5.2°C) and derived using the MS/TC protocol. 
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Changes in the CD4+ counts over days from baseline for samples stored at refrigerator 
temperature at the two laboratories are shown in Figures 4.17 and 4.18. On the whole, the 
deterioration in integrity and change from baseline CD4+ counts of samples analysed at the 
CDC laboratory occurred at a slower rate than was observed of samples analysed at the 
Johannesburg laboratory.  
 
Figure 4. 17: Change in Mean CD4+ Counts as a Ratio of Baseline over Days for samples stored at 
Refrigerator Temperature and derived using the 4-colour TetraONE protocol at the Johannesburg 
Laboratory or using the 4-colour MS/TC at the CDC Laboratory. 
Legend: Horizontal line at 90 – shows the sample Integrity Limit set at 90% similarity of Day reading to 
Baseline. Days labeled 1-8 for Johannesburg laboratory have actual estimated respective ages of ≥1-2, 
≥2-3, ≥3-4, ≥4-5, ≥5-6, ≥6-7, ≥7-8 and ≥8-9 days. 
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Figure 4. 18: Mean difference in CD4+ Counts to Baseline over Days for samples stored at Refrigerator 
Temperature and derived using the 4-colour TetraONE protocol at the Johannesburg Laboratory or 
using the 4-colour MS/TC at the CDC Laboratory. 
Legend: Horizontal line at 40 – shows the sample Integrity Limit set at a mean difference of 40cells/µl 
between day and baseline readings. Days labeled 1-8 for Johannesburg laboratory have actual estimated 
respective ages of ≥1-2, ≥2-3, ≥3-4, ≥4-5, ≥5-6, ≥6-7, ≥7-8 and ≥8-9 days. 
 
In summary, blood samples received at the Johannesburg hospital were on average ≥12-24 
hours old at the time they were received for testing by the laboratory. Most had been bled 
in the late afternoon or early evening the day before they were delivered to Johannesburg 
hospital for testing when the laboratory opened. 
In the hands of the writer, when the >90% integrity limit was used, samples processed 
using the international guideline protocol, 4-colour TetraONE, could only be used for up to 
48 hours (only 1 day from receipt into the laboratory and up to 2 days from the time of 
venesection) if kept in motion or when stored at refrigerator temperature. However, if 
samples were stored at room temperature, they could be used to derive precise and accurate 
CD4+ counts for up to 72 hours (2 days from receipt into the laboratory and up to 3 days 
from the time of venesection. Reliable CD4+ counts could not be obtained beyond 24 
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or in a refrigerator or at room temperature or at 37°C in a water bath, if the integrity limit 
of < 40 cells/µl was used.  
 
Use of the 2-colour PLG gating strategy only extended the window of testing samples 
stored at refrigerator temperature when the >90% integrity limit was used.  These samples 
could be kept and used for at least a day longer i.e. up to 72 hours (2 days from receipt into 
the laboratory and up to 3 days from the time of venesection). When the <40 cells/µl mean 
difference limit was used, use of the 2-colour PLG strategy extended the window of testing 
samples kept in motion and those stored at refrigerator temperature to 72 hours (2 days 
from receipt into the laboratory and up to 3 days from the time of venesection). It was also 
able to extend the window of testing samples stored at room temperature to 96 hours (3 
days from receipt into the laboratory and up to 4 days from the time of venesection).  
 
CD4 testing at the CDC laboratory was performed using the same international guideline 
but different manufacturer protocol, viz. the 4-colour MultiTEST/TruCount. All the 
samples tested at the CDC laboratory were on average about 5 hours old at the time of 
receipt into the laboratory and about 6 hours old when they were processed for baseline 
CD4+ counts. 
When the >90% limit and the <40 cells/µl mean difference limit were used, samples kept 
in motion could only be used to derive precise and accurate CD4+ counts for a maximum 
of 24 hours (1 day from receipt into the laboratory). Samples stored at room temperature 
could be used for up to 72 hours (3 days from receipt into the laboratory) while those 
stored at refrigerator temperature could be kept up to 144 hours (6 days from receipt into 
the laboratory). Precise and accurate CD4+ counts could not be obtained at all when 
samples were kept at 37°C in a water bath. 
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4.3 Evaluation of the use of a Commercial Whole Blood Stabilising 
Agent to enable Extending the Window of CD4 Testing. 
The change over time of CD4+ counts of samples drawn in new (2ml) commercial blood 
stabilisation tubes (BDB) was assessed in order to evaluate the efficacy of the stabiliser 
(Streck Laboratories, Omaha, NE) in the tubes to extend the window of CD4 testing.  
Table (4.31) summarises the results obtained when CD4+ count data for the 20 samples 
kept at room temperature (17-23°C) were analysed using the 4-colour MS/TC protocol 
(BDB) at the Johannesburg laboratory. The mean CD4+ count of the 20 samples analysed 
at baseline was 303 cells/µl and the range (54 – 747 cells/µl) but this dropped to a mean of 
281 cells/µl, range (50 – 850 cells/µl) by Day 7. Only 19 of the 20 samples had sufficient 
volumes for analysis on day 8 of follow-up. 
Table 4. 31: Summary of mean change in CD4+ counts of samples drawn in the new BDB tubes and 
derived using the 4-colour MS/TC Protocol at the Johannesburg laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
CD4 count 
Range 
Mean CD4 
count 
  
SD 
  
LOA 
Baseline <4 20 54 - 747 303 161.11  
6 144 20 53 - 811 285 169.69 (624.38, -54.38) 
7 168 20 50 - 850 281 181.98 (644.96, -82.96) 
8 192 19 95 - 845 286 173.22 (632.44, -60.44) 
 
Tables (4.32) below shows how long samples drawn in the new stabilisation tubes could be 
stored at room temperature before preparation and analysis. Samples could not be used to 
derive precise and accurate CD4+ counts by 144 hours (6 days from venesection) when the 
>90%, >95% limit and <20 cells/µl mean difference limit were each applied. Samples 
could however be kept and reliably analysed for up to 168 hours (7 days from venesection) 
when the <40 cells/µl mean difference cutoff was applied (p = 0.0447) confirming the 
manufacturer’s (BDB) claim about the product. 
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Table 4. 32: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline for 
samples drawn in the new BDB Tubes and derived using the 4-colour MS/TC Protocol at the 
Johannesburg Laboratory 
p value at Cut-
off p value at Cut-off Day post 
venesection 
Ratio of Mean  
Day CD4 count 
to Baseline as a 
(%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
6 93.05 10.21 0.0986 0.7978 17.80 35.73 (1.1,34.5) 0.0060 0.3930 
7 90.08 12.14 0.4882 0.9571 21.50 46.23 (-0.1, 43.1) 0.0447 0.5569 
8 88.41 12.35 0.7090 0.9840 29.32 45.33 (7.5, 51.2) 0.1589 0.8089 
 
Table (4.33) summarises the CD4+ count results of the 69 samples drawn in the new 
stabilisation tubes that were derived using the 4-colour MS/TC protocol (BDB) at the CDC 
laboratory. The mean CD4+ count of the 69 samples analysed on day 1 (considered as the 
baseline since the samples were > 24 hours old at time of receipt into the laboratory) was 
472 cells/µl and the range (69 – 1217 cells/µl) but this dropped to a mean of 460 cells/µl, 
range (56 – 1452 cells/µl) by Day 6. Only 33 of the 69 samples had sufficient volumes for 
analysis on day 8 of follow-up.  
 
Table 4. 33: Summary of mean change in CD4+ counts of samples drawn in the new BDB tubes and 
derived using the 4-colour MS/TC Protocol at the CDC Laboratory 
Day post 
venesection 
Age of samples 
(hours) 
No. of  
Samples 
Range of 
CD4 Counts 
Mean CD4 
Count 
  
SD 
  
LOA 
Baseline ≥24-36 69 69-1217 472 234.05  
4 96 69 68 - 1187 449 236.25 (921.5, -23.5) 
6 144 69 56 - 1452 460 246.10 (952.2, -32.2) 
8 192 33 46 - 1041 430 215.30 (860.6, -0.6) 
 
Samples at the CDC laboratory CD4+ counts could still be used to derive reliable CD4+ 
counts up to day 8 (192 hours from venesection) if the >90% similarity limit was applied 
but could not be used by day 4 (96 hours from venesection) if the other 3 limits were each 
applied (data is shown in Table 4.34). 
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Table 4. 34: Change in mean CD4+ counts as a ratio of baseline and mean difference to baseline for 
samples drawn in the new BDB tubes and derived using the 4-colour MS/TC Protocol at the CDC 
laboratory 
p value at Cut-
off p value at Cut-off Day post 
venesection 
Ratio of Mean 
Day CD4 count 
to Day 1 as a (%) 
SD 
90% 95% 
Bias SD 95% CI 
40cells/µl 20cells/µl 
4 96.25 18.09 0.0028 0.2846 23.52 104.43 (-1.6, 48.6) 0.0972 0.6099 
6 97.12 14.77 0.0001 0.1191 12.07 80.15 (-7.2, 31.3) 0.0026 0.2071 
8 97.42 15.07 0.0040 0.1811 18.70 76.20 (-8.3, 45.7) 0.0590 0.4612 
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5.0 DISCUSSION 
CD4+ T lymphocytes play a central role in the pathogenesis of HIV and are of prognostic 
value as predictors of progression to AIDS(8-10, 12). CD4+ counts are used in guiding 
decisions on the initiation and administration of ART(13, 14) and are used as a surrogate 
marker for drug efficacy in clinical trials(19). Measuring these T-cells is one of the most 
important immunological parameters used in the staging and management of HIV-1 
infected persons(5-7). It is therefore critical that CD4+ counts are accurately and precisely 
enumerated to ensure adequate monitoring of treatment for HIV infected patients(3, 61). 
Although CD4+ testing is now a routine test, variability between patient counts currently 
exists, especially in samples with low CD4+ counts (< 200 cells/µl)(6, 40, 47). Similar to 
reports from other studies(53, 60, 144), the results of this study showed that the reliability 
of reported CD4+ count results was heavily dependent upon the age of the sample at time 
of processing, procedures in which blood samples were handled, processed, and analysed 
in the laboratory, as well as the skills of the operator and methods used.  
In this study, the effect that certain factors had on accurate and precise enumeration of 
CD4+ cell counts was assessed. Specific factors tested included operator’s pipetting, 
preparative and analysis skills, gating (which specifically affect precision or reporting), 
storage temperature, motion, use of different protocols and manufacturer products, and the 
use of different flow cytometers. Furthermore, the efficacy of a new blood stabiliser was 
tested to evaluate the manufacturer’s claim that it could extend the window of CD4 testing. 
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5.1 Analyses performed to Assess Impact of CD4 Methodology 
including Specific Reagents, Flow Cytometry System, Protocol 
Setup and Gating, on Bias of CD4 Reporting. 
5.1.1 Assessment of Bias introduced through Poor Precision of Pipetting 
Consistent with previous reports(37, 41, 52, 53), this study showed that a laboratory’s 
competence to provide quality CD4+ count testing was dependent upon well trained 
operators and precise pipetting. Data on declining coefficients of variation (%CV) obtained 
in this study indicated that gradual improvement in precision was a direct consequence of 
time invested in the development of an operator’s pipetting skill. The operator’s (the 
writer’s) %CV decreased from 0.912% to 0.387% over 11 days of practice, suggesting that 
the more skilled an operator became, the greater the probability of obtaining consistent and 
more reliable CD4+ counts. This observation is in agreement with the lower within-
laboratory variation (%CV= 4.75%; range 2.51-6.20%) obtained at the Johannesburg 
laboratory. Technicians in Johannesburg received pipette training before participating in 
routine testing of patient samples and regularly had their pipetting skills assessed to ensure 
continued quality of CD4 results. In contrast, a higher within-laboratory variation (%CV= 
7.5%; range 3.61-9.28%) was observed at the CDC laboratory where the technicians had 
not received ongoing pipette training. 
 
5.1.1.1 Operator skill assessment (Forward pipetting versus Reverse pipetting 
precision assessment of the operator [Intra-operator]) 
In agreement with previous findings(153), this study also showed that establishing the 
pipetting technique upfront, i.e., either reverse pipetting or forward pipetting, showed 
improved operator consistency, with enhanced accuracy and precision of pipette 
measurements. The results showed that it was necessary to evaluate an individual’s 
pipetting skill so that the individual consistently used the technique with which they 
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obtained better precision (lower %CVs)(153). In this study, the writer obtained better 
pipetting precision using the forward pipetting technique (mean %CV = 0.513%) than 
using the reverse technique (mean %CV = 1.214%). The forward pipetting technique was 
therefore used in all the pipetting procedures.  
5.1.1.2 Within-laboratory pipetting skills precision assessment (precision between 
different operators at two different geographically located sites [Inter-
operator]) 
i) Within-laboratory (within and between-operator) precision 
Lower within-laboratory variation (%CV = 4.75% compared to %CV = 7.5%) resulted in 
lower variation in a patient’s CD4+ count when a sample was processed and analysed by 
ten different technicians at the Johannesburg laboratory (mean CD4+ count for the 10 
operators = 261 cells/µl; median = 260 cells/µl; range: 225-293 cells/µl; STDEV = 12.4). 
The greater variation observed in a patient’s CD4+ count (mean CD4+ count for the 10 
operators = 261 cells/µl; median = 262 cells/µl; range: 217-318 cells/µl; STDEV = 19.6) at 
the laboratory (CDC) with a higher within-laboratory %CV could impact the accuracy of 
CD4+ counts (see Table 5.1) by as much as 60 cells/µl between the best and worst 
operators; a 60 cells/µl difference would not have been an acceptable difference based on 
the criteria defined prior to the onset of this study. In contrast however, wider within-
laboratory variation has been reported in a recent U.S. multisite study, where it was shown 
that the median within laboratory predicate CD4 method %CV ranged from 4.0-8.7%(40). 
 
ii) Cell count related variation (within-operator variability) across strata of clinical 
CD4+ counts. 
The operator (the writer) at the Johannesburg laboratory who received pipette training 
exhibited greater pipetting precision than the operator at the CDC laboratory when they 
each analysed samples in different CD4+ strata. Better within-operator precision (%CVs of 
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4.95%, 2.92% and 2.83% compared to 6.44%, 5.20% and 5.41%) for samples with low, 
intermediate, and high CD4+ counts, respectively, was obtained by the operator at the 
Johannesburg laboratory, demonstrating that pipette training enhanced pipetting precision 
and reduced variation in patient CD4+ counts. However, as noted in previous studies(6, 
47), the precision of the two operators decreased with lower cell counts specifically, for 
CD4+ counts in the clinically relevant range. Here, variability was most likely to impact on 
treatment decisions and indicates the utmost importance of maintaining precision in this 
lower range of CD4+ counts.  
 
In Table 5.1 below, the impact that laboratory imprecision could have on patient 
management is discussed using the example of a hypothetical sample with a CD4+ count 
of 200 cells/µl (the current CD4+ count level at which the WHO and U.S. Public Health 
Service recommend that adult and adolescent ART and other prophylaxis are initiated(3, 
24). 
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Table 5. 1: A table illustrating hypothetical imprecision and estimated laboratory error around a 
CD4+ count in the clinically relevant range of 200 cells/µl at different levels of precision. 
  Hypothetical scenario 
  CD4+ count Precision (%CV) SD 2SD  
200 cells/ul± 2SD range 
Estimated expected range 
of error  
Hypothetical 200 3 (ideal) 6 12 (188 – 212) 
 200 5 10 20 (180 - 220) 
  200 6 12 24 (176 - 224) 
  200 7 14 28 (172 - 228) 
  200 8 16 32 (138 - 232) 
  200 9 18 36 (164 - 236) 
  200 10 20 40 (160 - 240) 
  200 12 24 48 (152 - 248) 
  200 15 30 60 (140 - 260) 
  200 18 36 72 (128 - 272) 
  200 20 40 80 (120 - 280) 
  200 25 50 100 (100 - 300) 
  
Summary of impact of within-laboratory pipetting precision on bias from this 
study 
261 7.5* 19.6 39.2 (161 - 239) 
Best precision 3.61 9.5 19.0 (181 - 219) CDC 
Worst precision 9.28 23.9 47.8 (152 - 248) 
261 4.75* 12.4 24.8 (175 - 225) 
Best precision 2.51 6.5 13.0 (187 - 213) Johannesburg 
Worst precision 6.20 16.6 33.2 (167 - 233) 
  Summary of impact of within-operator precision on bias from this study 
174  6.44 11.2  22.4  (152 – 196)  
 500 5.20 26.0  52.0  (448 – 552)  CDC 
 1327 5.41 71.8  143.6  (1183 – 1471)  
184 4.95 9.1 18.2 (166 - 202) 
449 2.92 13.1 26.2 (423 – 475) Johannesburg 
650 2.83 18.4 36.8 (613 - 687) 
* Mean laboratory %CV across 10 operators. 
 
The impact of poor precision on accuracy of CD4+ counts can be seen in Table 5.1. The 
table also reflects the findings of this study, which demonstrate that, with less precision, 
there is greater variance from the true value. This increases the probability that a patient 
would be falsely excluded from receiving treatment in time to prevent early death or in 
time to prevent the development of opportunistic infections and increased costs of treating 
these infections. Similarly, reporting inaccurately low CD4+ counts would also 
unnecessarily qualify patients for prophylaxis such as Mycobacterium avium complex 
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(MAC) therapy that is initiated at a CD4+ count of < 100 cells/µl(154). Further, for 
patients already on ART and where response to ART has been shown to be slow(155), 
reporting of small increases in CD4+ counts can be masked by wide variation of reporting 
from the servicing laboratory as illustrated in Table 5.1. Although viral load testing is 
typically used to decide response to therapy, in a scenario where CD4+ counts are the sole 
determinant for implementation and monitoring of ART, wide variation of CD4 reporting 
due to poor precision may give the false impression that a patient was showing poor 
immune and CD4 recovery (the CD4 recovery is masked by imprecision of reporting). The 
impact of the differences in precision noted across the laboratories evaluated in this study 
reveals that even relatively small differences in %CV/precision of reporting can result in 
differences of up to 40 cells/µl.  
While variation in intermediate and high CD4+ counts may not put patients at risk of 
immediate death, it would increase the cost of treatment and overburden health care 
systems which, in many cases, already have limited financial resources(40). Treatment of 
individuals erroneously deemed eligible could also result in the exclusion of patients from 
treatment who, with the treatment, would otherwise regain their health and continue to 
contribute socially and economically to their communities. 
 
5.1.2 Assessment of Bias introduced through use of Different Manufacturer 
Sample Preparation Systems, Different/Similar Gating Strategies, 
Different Flow Cytometers and Different Flow Cytometric Threshold.  
Similar to reports from other studies(38, 40, 41, 46), this study also noted differences 
between CD4+ counts when same samples were analysed using different protocols, 
different flow cytometers, different gating strategies, and when different flow cytometric 
threshold were used for data acquisition. Differences between CD4+ counts were also 
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observed between protocols and flow cytometers from the same manufacturer even when 
the same gating strategy was used.  
One instrument, the FC-500 cytometer (BCI, Miami, FL), consistently yielded results that 
were higher than those obtained from the other two instruments used viz.; the Epics-XL 
(BCI, Miami, FL) (see Table 4.3)  and the FACSCalibur (BDB) (see Tables 4.5 and 4.6) .  
There is an observed bias between CD4 results for a given sample analysed on different 
instruments. This occurred even when the same preparation methodology and the same 
gating analysis were used, which brings to light another critical factor; manufacturers do 
not typically calibrate their instruments with sufficient precision so that their instruments 
can be used interchangeably. Presently, the same model instrument cannot be used reliably 
for CD4 reporting, even within the same laboratory (personal communication – Lawrie D., 
Flow cytometry Laboratory, Johannesburg, South Africa)(152). Bias is frequently noted 
between instruments and between laboratories, even those using the same instruments. In 
some instances, differences have been noted even between laboratories using the same 
systems. An example is the differences in accuracy and precision observed in the BDB 
MS/TC system when two different gating methods are applied. One gating method which 
uses only primary CD3 gating (with CD4 and CD8) and the other which incorporates use 
of CD45bright gating (with CD3/CD4 and CD8), showed very different performances 
between laboratories(41) in terms of bias as well as precision between laboratories. 
These bias differences need to be addressed by insisting that instruments are calibrated 
with precision during installation and during maintenance servicing (personal 
communication – Lawrie D., Flow cytometry Laboratory, Johannesburg, South Africa). 
These results highlight the differences that are observed between 
instruments/methods/protocols used for CD4 lymphocyte enumeration. They highlight the 
need for laboratories that use more than one instrument or type of instrument, as well as 
groups of laboratories reporting CD4+ counts to the same network (e.g. across regional 
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study groups e.g. IAVI, AACTG, IMPAACT(156-158)) or across National country 
programmes, to validate CD4 instruments and additionally, preferably standardise the 
methods/protocols used. Usually, based on moderate workloads, laboratories only use a 
single instrument (flow cytometer) for CD4 testing. However, when multiple instruments 
are used to accommodate high workloads or when a group of laboratories supports the 
same service or study network, the impact of bias introduced across the numerous 
instruments can be marked. Further, the more variables there are in the sample preparation 
and analytical steps (viz. different methods, protocols, threshold, gating strategies), the 
greater the probability of introducing even more variation and hence more bias, between 
methods/instruments. Although the differences observed between 
instruments/methods/protocols were not clinically relevant in some parts of this study 
(clinical significance in this study was defined at two levels; a bias of 20 cells/µl and bias ≥ 
40 cells/µl), these results demonstrate the relevance and importance of standardising or 
alternatively, minimising on the variables between testing procedures both within- and 
between laboratories, to ensure comparability of CD4+ count results. Better reproducibility 
and precision in laboratory performance has been reported in studies where standardised 
systems were used(39, 41, 60). 
 
5.2 Analyses performed to assess the Impact of Logistical Factors and 
Time from Venesection, including Transportation and 
Temperature on Bias of CD4 Reporting. 
5.2.1 Assessing the Effect of Motion on Whole Blood Sample Integrity 
A large number of the samples received for testing at many of the central laboratories in 
Africa, are from remote areas. These samples are often transported to the testing laboratory 
by road for varying lengths of time and distances. However, most road networks in much 
of Africa are not well developed and so samples end-up being damaged in a vehicle during 
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transit. To assess the effect of sample handling on sample integrity, samples were kept in 
constant motion on a rocker or mixer for several days in an attempt to emulate a “bumpy 
drive” during transportation. 
Significant levels of sample deterioration and higher variation in CD4+ counts from 
baseline CD4+ counts were observed for the samples kept in motion when compared to 
samples left lying still in a refrigerator or on a laboratory bench at room temperature. This 
finding strongly reflected the impact that poor handling can have on sample integrity. The 
samples kept motion could only be used to accurately derive CD4+ counts within one day 
after receipt into the laboratory if 4-colour CD45bright lymphocyte based gating protocols 
were used and extended up to 2 days after receipt into the laboratory (3 days after 
venesection), if the 2-colour PLG protocol was used. In this instance, the use of the 
CD45bright lymphocyte based gating obscured the definition of the CD45bright lymphocyte 
population due to its merging with the dimmer CD4+ monocyte population as samples 
deteriorated, making the enumeration of CD4+ lymphocytes more difficult. CD4+ counts 
by the PLG methodology were less affected in this context as the total white blood cell 
population is the reference population from which the CD4+ cells are counted (instead of 
the CD45bright gating). However, the CD4% lymphocyte values generated in the PLG 
protocol were similarly affected by the merging of CD45bright lymphocytes and dimmer 
CD4+ monocyte populations. 
5.2.2 Assessing the effect of Temperature on Whole Blood Sample Integrity 
The temperature at which samples are stored during handling and just before analysis in 
the laboratory can ultimately have an effect on the integrity of samples and on precise 
enumeration of CD4+ counts. In agreement with current recommendations for testing(64), 
results from this study showed that samples could be kept at temperatures of (17–23°C) 
and analysed for reliable CD4+ counts for up to 3 days from venesection if 4-colour 
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CD45bright lymphocyte based gating protocols were used and longer (4 days), if the 2-
colour PLG protocol was used. However, as previously reported(64), temperatures over 
30°C caused the greatest variation from baseline CD4+ counts. This study showed that 
significant deterioration in sample integrity occurred soon after venesection when samples 
were kept at 37°C, causing samples to be unsuitable for reliable CD4+ counting. 
Contrary to reports by Weiblen B.J et al, 1983(159) and Dzik W.H, et al, 1983(160), the 
study data were in agreement with findings by Paxton H and Bendele T, 1993(131) which 
showed that whole blood samples could be safely stored at refrigerator temperature (4-6°C) 
and reliably used for CD4+ count enumeration. Although conclusions on the duration 
samples could be kept before testing differed between the two laboratories, results from 
both laboratories still supported storage of samples at refrigerator temperature. 
In an attempt to explain the difference in the window of testing, fluctuation in refrigerator 
temperature beyond (4-6°C) was ruled out since the refrigerators had been connected to 
stable power supplies (the CDC refrigerator in particular, was connected to an inventor 
supported power supply). As noted in this study and by others, possible explanations for 
the difference in results were attributed to the age of the sample at the time of refrigeration, 
the use of different CD4 testing protocols(38), differences in the populations that were 
studied(119) and to differences in the number of samples analysed at the two 
laboratories(161). In comparison with the samples received for testing in Uganda, the 
integrity of the samples received at the Johannesburg laboratory was compromised at the 
time of receipt and had deteriorated prior to processing (as evidenced by the deterioration 
of the granulocytes in the light scatter analysis). Samples received at the CDC laboratory 
were analysed for baseline CD4+ counts much sooner after venesection (6 hours) than 
samples at the Johannesburg laboratory (samples were estimated to be at least 12-24 hours 
old at the time of receipt in the laboratory). In addition, the samples processed at the CDC 
laboratory had been collected from sites in close proximity (5 – 38 km) to the laboratory 
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and may therefore have been less exposed to fluctuations in temperature and/or damage 
during transit. Fluctuations in temperature and movement have been reported to cause 
sample deterioration(162) and could perhaps explain why the results on the duration of 
testing samples at the Johannesburg laboratory differed from those previously shown(163). 
Scott, et al, showed that CD4 testing performed using the 2-colour PLG method could be 
extended up to over 5 days. However, samples used in their study had been drawn and 
delivered directly to the laboratory where they were stored at a constant temperature, left 
lying on the laboratory bench, and minimally handled for the entire period of testing. 
Further, although care was taken to ensure that the standardised Johannesburg TetraONE 
protocol including both a CD45bright and a PLG gate, was applied in this study, differences 
were noted between these results and those of Scott et al, or data from Beckman 
Coulter(162). Although a similar Forward Scatter (FSC) threshold was applied, higher FSC 
voltage settings than those used in the standardised protocol were applied resulting in non-
leucocyte events (i.e., platelets and debris) being included in the PanLeucogate (Gate A) 
and negatively affecting the final PLG CD4+ count (see Figure 5.1 in Appendix G). This 
may also have been the main contributing factor in the significant bias noted between 
gating methods when all other variables were equal (i.e., CD45bright vs. PLG on the same 
listmode data).  
Overall, these results strongly emphasise the need for attention to the manner in which 
samples are handled, stored, processed, and analysed. It has been reported that samples 
should be maintained at cooler temperatures (17-23°C) immediately after venesection, 
through transit, during any handling, and finally, in the laboratories, to avert deleterious 
effects that increased temperatures could have on sample integrity(64).  The results here 
further suggest the need for laboratories to independently determine the most suitable 
method of handling samples. Relevant factors for consideration include transportation and 
storage temperatures and conditions prior to sample testing. Storage of samples at room 
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temperature would probably be the easiest and most practical option but it needs to be 
emphasised that temperatures should be maintained within a specified range, (preferably 
between 17-23°C).  
Sample storage at refrigerator temperature is a good option for regions that experience 
temperatures that exceed 30ºC. However, it is important to stress that storage of samples is 
evaluated by laboratories to assess what works and best fits their local scenario. Local 
logistic analysis studies similar to these performed in this study would be of value in this 
context to determine best sample stability. The results of this study suggest that sample 
integrity is better maintained if samples are refrigerated as soon as possible after 
venesection. 
 
5.3 Evaluation of the use of a Commercial Whole Blood Stabilising 
Agent to enable Extending the Window of CD4 Testing.  
Stabilisers are added to blood to maintain the integrity of cells surface markers so that, if 
samples cannot be processed immediately after venesection, processing can be done at a 
later time and reliable results still obtained. A good stabilising agent should extend the 
window of testing without compromising the integrity of the samples. The advantage of 
using such a stabiliser is that it would improve accessibility to testing especially for remote 
sites that very often, in resource poor settings, lack laboratory facilities and have to send 
samples to centralised sites for testing. A good sample stabilising agent would also 
eliminate costs that accompany decentralised laboratory services and would therefore 
facilitate the centralisation of facilities and skills. This in turn, would simplify monitoring 
and implementation of quality control programmes, service delivery and logistics of 
maintaining the laboratories(164).  
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In this study, it was not possible to conclude whether the stabiliser actually ensured 
reliability of CD4 testing for the period claimed by the manufacturer. These results were in 
contrast to previously published work that confirmed extended window of testing using the 
new 2ml BDB tubes(165). In our study, data for 20 fresh samples (< 4 hours old at 
baseline) analysed at one of the laboratories showed that samples could not be used by day 
six from venesection. However, data from 69 samples analysed at the second laboratory 
showed that testing could be extended up to 8 days from venesection. This difference in 
results may have been due to differences related to the patient groups studied, differences 
in the batches of vacutainer tubes, differences in the TruCount kits used and possibly due 
to differences in operator skill at the two sites. The disparity of these results however, 
necessitates further evaluation of the efficacy of this stabiliser. If this is done, it should be 
noted that the 2ml tubes were taken off the market and re-launched as 5ml tubes after it 
was noticed that haemolysis of the samples occurred in high altitude regions if a full blood 
draw (2ml) was not made. Some haemolysis was noted in samples drawn in these special 
vacutainer tubes in the Johannesburg group (personal communication – Lawrie D.), which 
may also have contributed to the poorer results and failure to reach the supplier’s claim for 
the product at this center.   
Several other studies that evaluated the efficacy of different blood stabilising agents have 
shown that the window of CD4 testing could be extended for varying lengths of time 
(days) depending on the type of stabiliser, the concentration at which the stabiliser was 
used and depending on the temperature at which the stabilised/fixed samples were stored 
prior to analysis (i.e. 4°C, 25°C, 37°C or 42°C)(166-169). 
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6.0 CONCLUSIONS 
Variation in patient CD4+ counts and variation of counts noted between laboratories has 
been reported to influence clinical management of HIV patients(61). Its impact, especially 
in patients with low CD4+ counts or those with full blown AIDS and therefore critically in 
need of ART and other prophylaxes, raises two main concerns. Firstly, there is a need to 
educate all concerned parties of the role and importance of ensuring quality diagnostic 
services for CD4 testing in the decision making process and clinical management of 
patients. Secondly, there is a need to train laboratory personnel and equip laboratories with 
tools to provide these high quality services. Some recommendations for optimal testing 
conditions therefore include:  
Encouraging laboratories to use “Good  clinical laboratory practice” (GCLP) including the 
use of daily internal quality control (IQC) tools/materials and participation in external 
quality assessment schemes (EQA). IQC enables a laboratory to monitor the day-to-day 
quality of sample processing, the performance of personnel, test procedures, reagents and 
instruments to ensure accuracy, reliability and reproducibility of results. EQA, on the other 
hand is the evaluation of the performance of the laboratory in question versus the 
performance of a number of laboratories using specially supplied samples. It is performed 
by an external agency and its main objective is to continually monitor the standard of a 
laboratory’s performance and accuracy of reporting in relation to peer-laboratories. EQA is 
helpful for identifying systematic errors in a laboratory that IQC may fail to detect(41) and 
for assessing longitudinal performance over time. It is a valuable platform for assessing 
training needs, implementing on-going teaching and evaluation of how CD4 methodologies 
are used(41, 52). It is therefore a useful tool for observing inter-laboratory and inter-
machine reliability and can serve as a reliable resource for policy makers who wish to 
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review performance of laboratories using various CD4 systems(41). Both IQC and EQA 
participation have been reported to significantly improve quality of testing(41, 46). 
Where possible, CD4 methods, systems and protocols used could be to improve reliability 
and comparability of CD4 testing within and between-laboratories(39-41, 43-45, 55, 60, 
87, 94, 148, 150). Standardisation would not only be more cost-effective and ensure a 
tighter between-laboratory precision for CD4 reporting, but would simplify procurement of 
supplies, service delivery, training, and management of quality assurance 
programmes(164). The same protocol/method/instrument must consistently be used and, if 
any changes need to be made, the new protocol/method/instrument must be validated 
before being put into use. 
 
Laboratories may also have to take on the responsibility of ensuring that samples submitted 
for testing meet set criteria based on international guidelines(64). Samples must be drawn 
in the correct collection tubes (EDTA) and these filled to a correct volume (i.e. correct 
EDTA to blood ratio) to ensure the accuracy and precision of results(130). Samples must 
also be kept and transported at appropriate temperatures. Where available, ice packs or ice 
cubes wrapped in disposable plastic bags and newpaper to insulate and prevent direct 
contact with the samples, could be fitted around the samples in the transportation 
containers (cooler boxes) to cool temperatures during transit. Temperature-monitoring 
devices similar to the kind developed by WHO/UNICEF for monitoring vaccine 
deliveries(170) could also be placed in the transportation containers to monitor temperature 
during transit. Temperature readings could then be noted on delivery of samples to the 
laboratory and this information used to assess if samples were still suitable for testing.  
In order to minimise damage of the samples during transit, samples could be placed into 
vertical tube racks and the racks placed into the transportation containers and fitted around 
with soft paper (old news paper, cotton wool or bubble wrap) to act as shock absorbers and 
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as a cushion to keep the samples in fixed positions. Transportation containers must not be 
roughly handled and should be kept from being tossed about or toppled over during the 
drive to the laboratory. 
 
Field workers (phlebotomists, drivers) and laboratory staff should be educated, trained and 
provided with written, easy to follow standard operating procedures (SOPs)/guidelines on 
sample quality, sample collection, sample handling and transportation. However, as 
important as the education and training are, these would be pointless if the knowledge is 
not implemented. The onus would therefore be on the laboratory management teams to see 
to it that SOPs and good clinical laboratory practice (GCLP) are implemented and 
maintained. 
 
Samples received for testing must be clearly labeled with a date and time of collection or 
submitted with this information to ensure that the samples are both suitable for testing and 
are processed within the acceptable time frame. On receipt, samples must be stored within 
the temperature range established as most suitable by the laboratory. During hot seasons in 
laboratories without air conditioners, samples could be stored in well ventilated areas and 
away from direct sunlight to minimise temperature increases. Alternatively, the samples 
could be left in the transportation containers/cooler boxes with ice packs/ice blocks until 
testing. In case the latter are unavailable, samples could be placed into vertical tube racks 
and the racks placed in open containers containing cold water (between 17–25°C) to 
immerse at least half the height of the sample tubes.  
In preparation of samples for processing, prolonged mixing of the samples should be 
avoided and only proper blood rockers should be used (circular mixers tend to cause 
sedimentation and are only useful for chemistry analyses). 
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Test reagents and kits must validated before being put into use and used before the expiry 
date and in accordance with manufacturer guidelines. 
Laboratories should ensure that pipettes are calibrated and validated before being put to 
use. The pipetting skills of operators should be assessed and regularly monitored as part of 
in-house quality control measures to minimise errors. Whole blood (not distilled water) 
must be used in these pipetting exercises to avoid volume errors that may otherwise occur 
due to the difference in viscosity of blood and water(64).  
 
Several studies have also shown that the effect of diurnal variation is minimised if patient 
samples are repeatedly drawn at a specified time of day or time interval (e.g., between 8am 
– 12noon)(49, 51). Laboratories could be encouraged to do this, especially if they provide 
routine follow-up CD4 testing. 
 
Lastly, laboratories (the users) and instrument manufacturers should be encouraged to 
partner in the effort to improve quality of CD4 testing. Closer interaction between the two 
groups could be used as a training/learning tool and to address loopholes in the 
systems/policies in use; the requirement to use specific pipettes/pipetting technique and 
bias between methods and instruments are cases in point. 
This study provides information about causes of variation in CD4+ counts enumerated 
using different flow cytometry methods and provides some insight into how the quality and 
consistency of CD4+ testing can be improved both within and between laboratories. 
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7.0 LIMITATIONS 
Repeatability of the study was not assessed between laboratories in the same country or 
using the same batch of samples. Such reproducibility and extended window studies would 
probably have provided a clearer conclusion of what temperature was most conducive for 
sample storage. Using the same number and batch of blood samples could have ruled out 
the differences in results obtained at the two laboratories and probably provided better data 
for comparison. 
 
The ‘actual’ variability in CD4+ counts caused by the flow cytometers (instrument 
precision) was not assessed using a singly prepared sample. Performing this evaluation 
would have required that a prepared sample be acquired repeatedly (at least 10 times) for 
meaningful interpretation of a calculated %CV of the replicates. However, this could not 
be done because the prepared sample volume were too small to obtain 10 replicate CD4+ 
counts i.e. the (500µl) sample volume used in the MultiTEST/TruCount protocol or the 
(1ml) volume used in the PLG-CD4 and TetraONE protocols. Instrument precision was 
however tested daily (and optimally ensured) at the Johannesburg laboratory using bead 
count rates where precision of instrument fluidics was monitored daily(152). 
 
An assessment of variation between same model cytometers i.e. Epics-XL versus Epics- 
XL or FACSCalibur versus FACSCalibur, to provide the basis for a comparison between 
different models from different manufacturers i.e. Epics-XL versus FACSCalibur, was not 
performed. It is recommended that such studies are followed up especially with the view to 
establishing standardisation of calibration between instruments and minimising bias in 
CD4+ counts within laboratories using more than one flow cytometer (as is the case in the 
Johanessburg laboratory where five Epics-XL instruments are used). With respect to the 
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BDB system, unfortunately, neither laboratory had more than one FACSCalibur flow 
cytometer to compare the MS/TC protocol between instruments in the same laboratory. 
 
Further, as there already exists a good supporting body of literature which shows the 
existance of bias between CD4 methods(25-27, 29-31, 33, 40, 43, 45, 54-60), it was not 
considered within the scope of this study to include an assessment of bias between 
different platforms (DP versus SP) or bias introduced through use of other smaller systems 
(e.g., FACSCount, Guava and PointCARE systems).  
 
In accordance with standardised protocols of the Johannesburg flow laboratory and 
published work by Scott et al, Glencross et al and data contained in the PLG package insert 
(BCI, Miami, FL), the extended window study, especially with respect to the 2-colour PLG 
protocol used, was not properly optimised by the writer for this study and very likely 
affected the data showing extended window to just 3 days. It is recommended that the unit 
repeat this aspect of the study with special attention to forward scatter threshold setup and 
size discrimination settings to properly ensure that all platelet and other particulate non-
cellular fluorescenting debris (see Figure 5.1 in Appendix G) is excluded from the PLG 
gate. A specifically controlled study to assess the impact of transportation of samples (and 
temperature related issues during transportation) may further reveal interesting and relevant 
insights in how samples are potentially damaged during transit as well. 
 
Although a comparison in performance of the new 2ml BDB tubes against the standard 
EDTA tubes has previously been done(165), it was not done in this study. It would have 
been important to assess the effect of the stabilising agent by comparing CD4+ counts of 
samples drawn in the new tubes to those drawn in standard EDTA tubes, at baseline. 
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APPENDICES 
APPENDIX A: List of Other Instruments used in the Study. 
Other instruments used in the study included: 
i) Weighing balances 
 AAA 250/L Adams Balance  
 ALS Series Analytical Balance (Jencons – PLS, West Sussex, UK) 
ii) Vortex-Genie2 mixer (Scientific Industries, INC. Bohemia, N.Y. USA) 
iii) Roller Mixer (Thermo Denley SPIRAMIX)  
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 APPENDIX B: Description of Pipetting Techniques 
Procedure using the Forward Pipetting Technique.  
In forward pipetting, the pipette is set to a desired volume and a correct tip fitted to its tip 
cone. Thumb pressure is gently applied to the plunger until the first stop and the tip placed 
beneath the surface of the blood sample to be pipetted. The plunger is then smoothly 
released to draw up blood, the tip carefully withdrawn from the blood, its exterior wiped to 
remove excess blood and the aspirated blood expelled into a test tube by gentle application 
of pressure to the plunger until the second stop. 
 
Procedure using the Reverse Pipetting Technique. 
In reverse pipetting, the pipette plunger is pressed all the way to the second stop to allow 
for a slight excess of sample to be aspirated. Excess blood on the exterior of the tip is 
carefully wiped and the blood expelled into a test tube by gentle application of pressure to 
the plunger until the first stop. The excess blood left in the tip is discharged. 
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APPENDIX C: Samples kept in motion and analysed using the 
TetraONE protocol with 2-colour PLG gating. 
Table 4. 35: Change in Mean CD4+ counts as a Ratio of Baseline and Mean Difference to Baseline for 
samples kept in Motion and derived using TetraONE Protocol with 2-colour PLG Gating 
Ratio of Mean 
Day CD4 Count 
p value at Cut-
off p value at Cut-off 
Day post 
venesection 
to Baseline as a 
(%) SD 90% 95% Bias SD 95% CI 40cells/µl 20cells/µl 
≥1-2 96.24 9.82 0.0007 0.244 16.19 31.17 (4.8, 27.6) 0.0001 0.2509 
≥2-3 89.38 9.31 0.6431 0.9989 29.42 33.46 (17.1, 41.7) 0.0443 0.9362 
≥3-4 83.78 17.11 0.974 0.9995 51 61.03 (28.6, 73.4) 0.8382 0.9959 
≥4-5 71.34 14.46 1 1 89.94 68.22 (64.9, 115.0) 0.9998 1 
≥5-6 66.97 14.89 1 1 102.74 71.56 (76.5, 129.0) 1 1 
≥6-7 59.09 17.21 1 1 120.25 243.85 (25.7, 214.8) 0.9535 0.9807 
≥7-8 53.54 15.12 1 1 152.15 106.73 (102.2, 202.1) 0.9999 1 
≥8-9 54.28 12.64 0.9945 0.9962 199.25 263.52 (-220.1, 618.6) 0.8433 0.8666 
 
 
Table 4. 36: Change in Mean CD4% as a Ratio of Baseline over Days for samples kept in Motion and 
derived using TetraONE Protocol with 2-colour PLG Gating 
Day post Age of samples  Ratio of mean CD4% to 
venesection (hours) Baseline as a (%) SD 95% CI p-value 
≥1-2 36-48 102.08 5.85 (99.9, 104.2) <0.0001 
≥2-3 60-72 104.17 9.91 (100.5, 107.8) <0.0001 
≥3-4 84-96 110.55 11.4 (106.4, 114.7) <0.0001 
≥4-5 108-120 122.43 20.26 (115.0, 130.0) <0.0001 
≥5-6 132-144 129.74 27.52 (119.6, 139.8) <0.0001 
≥6-7 156-168 134.98 34.34 (121.7, 148.3) <0.0001 
≥7-8 180-192 145.25 21.53 (134.9, 155.6) <0.0001 
≥8-9 204-216 151.4 18.93 (121.3, 181.5) 0.0047 
Merging of the CD45bright population with nearby monocytes resulted in the samples not being suitable 
for use beyond 48 hours. 
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APPENDIX D: Samples stored at 37°C and analysed using the 
TetraONE protocol with 2-colour PLG gating. 
Table 4. 37: Change in Mean CD4+ Counts as a Ratio of Baseline and Mean Difference to Baseline for 
samples kept at 37°C in a Water Bath and derived using the TetraONE Protocol with 2-colour PLG 
Gating 
Day post 
Ratio of Mean 
CD4 count to 
Baseline as a p value at Cut-off p value at Cut-off 
venesection  (%) SD 90% 95% Bias SD 95% CI 40cells/µl 20cells/µl 
≥1-2 83.55 13.31 0.9943 1 44.55 31.44 (33.0, 56.1) 0.7865 0.9999 
≥2-3 75.30 20.50 0.9997 1 74.17 57.83 (52.2, 96.2) 0.9982 1 
≥3-4 41.39 23.09 1 1 174.77 147.61 (109.3, 240.20 0.9998 1 
 
Table 4. 38: Change in Mean CD4% as a Ratio of Baseline over Days for samples kept at 37°C in a 
Water Bath and derived using the TetraONE Protocol with 2-colour PLG Gating 
Day post Age of samples No of Ratio of mean CD4% to 
venesection (hours) Samples Baseline as a (%) SD 95% CI p-value 
≥1-2 36-48 31 103.59 10.61 (99.7, 107.5) <0.0001 
≥2-3 60-72 29 93.98 20.14 (86.32, 101.65) 0.606 
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APPENDIX E: Samples stored at 17-23°C and analysed using 
the TetraONE protocol with 2-colour PLG Gating. 
Table 4. 39: Change in Mean CD4+ Counts as a Ratio of Baseline and Mean Difference to Baseline for 
samples stored at Room Temperature (17-23°C) and derived using the TetraONE Protocol with 2-
colour PLG Gating 
Day post 
Ratio of Mean 
CD4 count to 
Baseline as a 
p value at Cut-
off p value at Cut-off 
venesection  (%) SD 90% 95% Bias SD 95% CI 40cells/µl 20cells/µl 
≥1-2 98.57 14.4 0.0012 0.0890 5.71 57.04 (-15.2, 26.6) 0.0011 0.0866 
≥2-3 94.69 9.86 0.0064 0.5696 12.58 28.54 (2.1, 23.1) <0.0001 0.0791 
≥3-4 90.78 11.48 0.3544 0.9753 24.84 29.33 (14.1, 35.6) 0.0037 0.8172 
≥4-5 86.83 9.75 0.9598 1 39.94 38.44 (25.8, 54.0) 0.4963 0.9964 
≥5-6 86.73 10.16 0.9583 1 36.10 29.85 (25.1, 47.0) 0.2361 0.9973 
≥6-7 82.24 10.72 0.9997 1 54.57 60.85 (31.0, 78.2) 0.8920 0.9972 
≥7-8 80.50 10.62 1.00 1 55.83 38.52 (39.2, 72.5) 0.9692 1 
≥8-9 75.95 11.61 0.9530 0.9768 103.00 73.43 (-13.9, 219.9) 0.9076 0.9456 
 
Table 4. 40: Change in Mean CD4% as a Ratio of Baseline over days for samples stored at Room 
Temperature (17-23°C) and derived using the TetraONE Protocol with 2-colour PLG Gating 
Day post Age of samples No of Ratio of Mean CD4% to  
venesection (hours) Samples  Baseline as a (%) SD 95% CI p-value 
≥1-2 36-48 31 102.22 6.10 (100.0, 104.5) <0.0001 
≥2-3 60-72 31 106.51 6.85 (104.0, 109.0) <0.0001 
≥3-4 84-96 31 109.37 12.2 (104.9, 113.9) <0.0001 
≥4-5 108-120 31 109.1 12.28 (104.6, 113.6) <0.0001 
≥5-6 132-144 31 109.24 11.23 (105.1, 113.4) <0.0001 
≥6-7 156-168 28 111.11 12.27 (106.4, 115.9) <0.0001 
≥7-8 180-192 23 111.37 12.55 (106.0, 116.8) <0.0001 
≥8-9 204-216 4 117.26 4.55 (110.0, 124.5) 0.0011 
Merging of the CD45bright population with nearby monocytes resulted in the samples not being suitable 
for use beyond 48 hours. 
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APPENDIX F: Samples stored at 4-6°C and analysed using the 
TetraONE protocol with 2-colour PLG Gating. 
Table 4. 41: Change in Mean CD4+ counts as a Ratio of Baseline and Mean Difference to Baseline for 
Samples stored at Refrigerator Temperature (4-6°C) and derived using the TetraONE Protocol with 2-
colour PLG Gating 
Day post 
Ratio of Mean 
CD4 count to 
p value at Cut-
off p value at Cut-off 
venesection 
Baseline as a  
(%) SD 90% 95% Bias SD 95% CI 40cells/µl 20cells/µl 
≥1-2 97.26 8.75 <0.0001 0.0806 11.39 25.49 (2.0, 20.7) <0.0001 0.0348 
≥2-3 93.37 9.42 0.0277 0.8278 21.26 29.75 (10.3, 32.2) 0.0007 0.5923 
≥3-4 85.16 10.3 0.9931 1 51.23 71.68 (24.9,77.5) 0.8049 0.9892 
≥4-5 78.95 12.11 1 1 64.97 69.12 (39.6, 90.3) 0.9733 0.9995 
≥5-6 78.73 14.88 0.9999 1 70.29 64.06 (46.8, 93.8) 0.9934 0.9999 
≥6-7 69.27 14.20 1 1 84.82 47.13 (66.5, 103.1) 1 1 
≥7-8 60.28 17.86 1 1 138.65 159.36 (64.1, 213.2) 0.9939 0.9982 
≥8-9 62.19 17.18 0.9987 0.9995 73.25 62.34 (21.1, 125.4) 0.9124 0.9768 
 
 
Table 4. 42: Change in Mean CD4% as a Ratio of Baseline over Days, for Samples stored at 
Refrigerator Temperature (4-6°C) and analysed using the TetraONE Protocol with 2-colour PLG 
Gating 
Day post Age of samples No of Ratio of Mean CD4% to  
venesection (hours) Samples  Baseline as a (%) SD 95% CI p-value 
≥1-2 36-48 31 98.93 5.66 (96.9, 101.0) <0.0001 
≥2-3 60-72 31 100.62 7.40 (97.9, 103.3) 0.0001 
≥3-4 84-96 31 98.34 5.93 (96.2, 100,5) 0.0019 
≥4-5 108-120 31 94.08 13.52 (89.1, 99.0) 0.6471 
≥5-6 132-144 0 0       
≥6-7 156-168 28 97.62 11.16 (93.3, 102.0) 0.1121 
≥7-8 180-192 20 99.90 13.87 (93.4, 106.3) 0.0653 
≥8-9 204-216 8 96.79 8.70 (89.5, 104.1) 0.2890 
 
  
 120 
APPENDIX G:  
 
Figure 5. 1: Figure illustrating the effect of poor threshold setting on accurate enumeration of CD4+ 
counts using the 4-colour TetraONE protocol. 
Further resulting in poor 
resolution of monocytes 
(identified within green dotted 
circle) and loss of (CD8+NK+) 
lymphocytes (identified within 
blue dotted circle); possibly due 
to over colour compensation 
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